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ABSTRACT
In vivo DNA is compacted tightly, via its association with histones and
non-histone proteins , into higher-order chromatin structure. In this state , the
DNA is refractory to the cellular factors that require access to DNA The
repressive nature of chromatin is alleviated in part by the action enzymes that
modify chromatin structure. There are two major groups of chromatin modifying
enzymes: those that post-translationally modify histones by the addition of small
chemical moieties and those that utilize the energy derived from ATP hydrolysis
to physically disrupt chromatin structure. The SWI/SNF enzyme belongs to this
latter group.
The SWI/SNF complex was identified originally in yeast. Several of its
subunits are required for the expression of a subset of inducible genes. The
ATPase activity is provided by the SWI2/SNF2 protein. In mammals , there are
two biochemically separable SWI/SNF complexes that contain either BRG1 or
BRM , both homologs of yeast SWI2/SNF2. The yeast and mammalian SWI/SNF
complexes are able to disrupt the Dnase I digestion pattern of in vitro assembled
mononucleosomes and arrays , as well as facilitate the accessibility of restriction
nucleases and transcription factors. The mechanism by which SWI/SNF
functions has yet to be elucidated.
SNF5 is a component of the yeast SWI/SNF complex. It is required for
sucrose fermentation and mating type switching. The mammalian homolog of
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Snf5 is SNF5/INI1. SNF5/INI1 was identified simultaneously by two groups as a
protein that shares homology with Snf5 and via a yeast two hybrid assay as a
protein that interacts with HIV integrase ( tegrase Interactor). INI1 is a
component of all mammalian SWI/SNF complexes purified to date.
In humans, mutations and/or deletions in INI1 are associated with a
variety of cancers , including malignant rhabdoid tumors , choroid plexus
carcinomas , medullablastomas , primitive neuralectodermal tumors , and some
cases of leukemia. Furthermore , constitutional mutations within INI1 
individuals presenting with these tumors support the role of INI1 as a tumor
suppressor.
In this thesis , we show that Ini1 also functions as a tumor suppressor in
mice. Approximately 20% of mice heterozygous for Ini1 present with tumors.
Most of these tumors are undifferentiated or poorly differentiated sarcomas with
variable rhabdoid features. All tumors examined to date show loss of
heterozygosity at the Ini110cus. We also show that Ini1 is essential for
embryonic development. Mice homozygous-null for Ini1 die between days 4 and
5 post-fertilization due to an inability to adhere to their substratum , form
trophectoderm , and expand their inner cell mass.
We further characterize the function of Ini1 in tumor suppression by
generating mice heterozygous for both Ini1 and either Rb or p53. While
heterozygosity at the Ini110cus appears to have no effect on the rate of
tumorigenesis in Rb-heterozygous mice , many of the tumors arising in compound
viii
heterozygous mice present with an altered morphology. This finding suggests
that Ini1 may contribute to tumor progression due to loss of Rb. In contrast, mice
compound heterozygous for Ini1 and p53 show a marked reduction in the rate of
tumorigenesis compared to p53-heterozygous mice. Furthermore , the tumor
spectrum is altered in these compound heterozygous mice. These findings
suggest that Ini1 may function normally to repress p53 activity.
Lastly, we show that expression of the Ini1 tumor suppressor itself is
regulated tightly. Tissues and cells heterozygous for Ini1 express roughly
equivalent levels of Ini1 protein and mRNA as their wild-type counterparts. We
further show that this compensation is mediated by an increase in the rate of
transcription from the wild- type Ini1 allele. Moreover, when exogenous Ini1 is
introduced into Ini1- heterozygous cells , expression from the Ini1 promoter is
reduced. These data indicate that a compensatory mechanism exists to ensure
that the steady-state levels of Ini1 are constant.
In summary, research detailed in this thesis has contributed to our
understanding of the regulation of Ini1 as well as the role this protein plays in
mammalian development and tumor suppression.
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Chapter I
Introduction
A Chromatin Structure
The core particle of chromatin structure is the nucleosome. Combined
data obtained from micrococcal nuclease digestion as well as x.:ray and electron
crystallography at 7 A resolution indicate that the nucleosome consists of
approximately 146 base pairs of DNA wrapped in 1.8 helical turns around the
histone octamer (61 , 168 240). The octamer itself has a (H3)2(H4)2 tetramer at
its center with an H2A-H2B dimer at each end of the DNA path. Each histone
has a polypeptide chain fold known as the "histone fold" (9). The histone fold is
formed by a long, central a-helix that is flanked on either side by shorter helices
and loops that interact with DNA At the amino terminal end of each histone are
15-30 residues that comprise the "histone tail". The histone tails appear
unstructured at this resolution.
The 2.8 A resolution crystal structure (Figure 1. 1) shows that the
phosphodiester backbones of the DNA strands on the inner surface of the
superhelix contact the octamer every ten base pairs , where the minor groove of
the double helix faces inward (144). The amino-terminal tails of both H2B and
H3 pass through the gap in the DNA superhelix formed by aligned minor grooves
to the outside of the core particle. The H2A and H4 tails pass across the
superhelix on the flat faces of the particle to the outside as well. The position of
Figure 1.1: 2.8 A resolution crystal structure of nucleosome core
particle (144)
the tails suggests that they are exposed. The 16-25 amino terminal residues of
the H4 tail extend into the adjacent nucleosome to interact with the negatively
charged face of the H2A-H2B dimer. This interaction may mediate higher order
folding.
The 1.9 A resolution x-ray crystal structure of a nucleosome core particle
containing 147 base pairs of DNA shows that water molecules and ions play an
important role in nucleosome structure (45). The water molecules serve as
hydrogen bond bridges between the histone proteins and DNA It has been
suggested that these bonds diminish the requirement for sequence specificity in
nucleosome positioning. Monovalent anions are located in proximity to the DNA
phosphodiester backbone and may partially neutralize the electrostatic
interaction between histones and DNA Divalent cations, bound at specific sites
in the nucleosome, contribute to histone-histone and histone-DNA interactions
between adjacent nucleosomes. As with the histone tail of histone H4 , these
divalent cations may participate in higher order folding.
The DNA between adjacent nucleosomes is called linker DNA The
histone H1 binds to the linker DNA near one end of the core DNA inside the
chromatin fiber (280). Chromatin fibers are composed of arrays of nucleosomes
linker histones , and trans-acting factors. In vitro, nucleosomal arrays adopt an
extended 10nm diameter or 30nm diameter fiber depending on ionic strength of
the medium. Tail- less chromatin fibers can neither fold into 30nm fibers nor form
fiber-fiber associations , suggesting that the tails play an important role in higher
_:"
order chromatin structure (37). The 30nm fiber is the basic component of both
interphase chromatin and mitotic chromosomes; however, the mechanism by
which these fibers are packed into the highly condensed, organized structure of
the mitotic chromosome is not well understood. Recent data indicate that a
macromolecular complex called condensin is required for proper chromosome
condensation , but how this complex functions is unclear (43 224).
Furthermore , the core histone tails , but not histone H1 , also are required for
mitotic chromosome condensation (47).
Chromatin structure generally inhibits the function of transcriptional
machinery. The packaging of promoters in nucleosomes prevents the initiation of
transcription by bacterial and eukaryotic RNA polymerases in vitro (116, 141). 
vivo when H4 synthesis is inhibited , several TAT A-containing promoters are
activated in the absence of their normal activation mechanisms (79).
Furthermore , in DNA microarray analysis , nucleosome loss results in activation
of 15% of yeast genes, not including the -40% of the yeast genome that is
constitutively active (75 , 265).
B. Chemical Modification of Chromatin Structure
The core histone tails , and in some cases the histone H1 tail , are
susceptible to a wide range of post-translational modifications , including
acetylation , methylation , phosphorylation , ubiquitination , glycosylation , and ADP-
ribosylation. The effects of these modifications on gene expression are varied.
While chemical modification of histone tails is not the focus of this thesis, some of
these modifications , including histone acetylation/deacetylation , methylation
phosphorylation , and ubiquitination are discussed in this introduction , with a
particular emphasis on their links to cancer.
1. Histone Acetylation
Hyperacetylation of histone tails has been correlated with increased gene
activity (72 83, 84 221). The regions of the histone tails that are acetylated
are conserved , often invariant , lysine residues. Mutation of acetylatable Iysines
in histone H4 of Saccharomyces cerevisiae shows that these residues are
required for activation of regulated genes. It is believed that the changes in the
charge of histone tails resulting from acetylation either weakens histone:DNA
contacts , alters histone:histone interactions between neighboring nucleosomes
or disrupts histone:regulatory protein interactions, or a combination of all three
(85, 144 , 145, 234 258).
Histone Acetyl Transferases , or HATs , are responsible for the acetylation
of histones. They can be divided into two categories: A-type and B-type. B-type
HATs are cytoplasmic and likely catalyze acetylation events linked to transport of
newly synthesized histones from cytoplasm to nucleus for deposition onto newly
replicated DNA (4 196). A-type HATs include nuclear HATs that likely catalyze
transcription-related acetylation events (25). The A-type HAT proteins can be
divided , based on sequence , into distinct familes that show high sequence
similarity within families but poor to no sequence similarity between families.
These families include the GNAT superfamily, the MYST family, the p300/CBP
family, the basal transcription factors , and the nuclear receptor cofactors (193).
The GNAT superfamily encompasses the GCN5-related N-
acetyltransferases (166). They contain limited sequence homology within four
15-35 residue , motifs (named A-D). This family includes the prototype
GCN5/PCAF , as well as Hat1 , Elp3, and Hpa2. The first description linking
histone acetyltransferase activity to gene activation came in 1996 with the finding
that the Tetrahymena histone acetyltransferase A had homology with the yeast
GCN5, a known transcriptional activator (24 25).
The MYST family is named for the founding members: OZ; bf2/Sas3;
as2; and Iip60. It also includes Esa1 , MOF, and Hb01. Many members of the
MYST family contain chromodomains (chromatin Qrganization difier), protein-
protein interaction domains often found in heterochromatin-associated proteins
(106). It is possible that these domains serve to target members of the MYST
family to chromatin targets. The MYST family has been linked to cancer via the
founding member, MOZ (monocytic leukemia zinc finger protein). As its name
implies MOZ is an oncogene , translocations of which are involved in certain
cases of monocytic leukemia (21 34). MOZis the human homologue of
yeast Ybf2/Sas3 , the catalytic subunit of NuA3 , a yeast HAT complex that
specifically acetylates histone H3 (70 , 105, 187). Though MOZ has not been
demonstrated to possess HAT activity, the sequence similarity to Sas3 suggests
that it is likely a HAT.
P300 and CBP were isolated independently as factors that interact with
adenovirus E1 A protein (p300) or with the phosphorylated form of the
transcription factor CREB (CBP) (41 58). Both share sequence similarities and
their function is interchangeable in vitro , 8, 146). Each contains three putative
zinc finger regions , a bromodomain (a domain that interacts with acetyl- lysine
residues), a HAT domain , and at least two independent regions that interact with
multiple transcription factors. They are transcriptional coactivators; they do not
bind DNA directly. They interact with many factors including, but not limited to c-
jun , c-myb , c-fos , TFIID , MyoD , nuclear hormone receptors , and E2F-1 (12
60, 101 , 102 , 108, 152 , 169, 197 , 273). Their HAT activities are required for their
functions in transcriptional activation (11 , 152 , 170).
The first line of evidence linking misregulation of HAT activity to cancer
came from the finding that the adenoviral E1 A oncoprotein targets p300/CBP (8,
58). Overexpression of E1 A prevents binding of p300/CBP to PCAF and induces
entry of cells into S phase (269). The transforming activity of E1 A depends on its
ability to interact with and sequester p300/CBP , as excess p300/CBP inhibits
E1 A-mediated cell immortilization.
The gene encoding CBP has been shown to be involved in chromosomal
translocations in certain leukemias. In acute myeloid leukemia , the
t(8;16)(p11 ;p13) translocation results in the fusion of CBP to the human
oncogene MOZ(21). This fusion creates a protein with two HAT domains.
Recruitment of this protein by CBP or MOZ cofactors may bring inappropriate
HAT activity to target promoters. In addition , two inversions within chromosome
8 that are associated with leukemia fuse MOZto transcriptional intermediary
factor 2 (TIF2), a p300/CBP interacting protein with intrinsic HAT activity (33, 34).
The resulting fusions retain the HAT domains of both proteins.
The t(11 ;16)(q23;p13) chromosomal translocation , found in many
leukemias , fuses CBPto MLUALL- (209). MLUALL- is the human homologue
of Drosophila trithorax, a protein that functions during development in
maintenance of open chromatin configuration for proper expression of homeotic
genes. Additionally, a MLL-p300 translocation has been described in a patient
with AML (94).
There is evidence suggesting that CBP is a bona fide tumor suppressor.
CBP heterozygosity is associated with Rubenstein- Taybi Syndrome (RTS), a
human disorder characterized by cranial and digital malformation , mental
retardation , hematopoietic abnormalities and higher risk for developing certain
types of cancer (155 180). CBP has been targeted in mouse knock out
experiments (122 , 171). CBP heterozygous mice display various developmental
defects and develop a high incidence of hematological malignancies , including
histiocytic sarcomas and myelogenous and lymphocytic leukemias.
Tumorigenesis is correlated with loss of heterozygosity in transformed cells.
The histone acetyltransferase p300 also may be a tumor suppressor. A
number of human tumors, including glioblastomas , colorectal cancers , and breast
cancer, show loss of heterozygosity of p300 (65 , 160). In a study examining a
variety of primary tumors or tumor cell lines for mutations in p300, ten of 193
were shown to have loss of function mutations (65). P300 has been targeted in
mouse knock out experiments (271). However, there have been no reported
cases of malignancy in p300 heterozygous mice.
Overexpression of some histone acetyltransferases has been correlated
with cancer. The nuclear hormone cofactor ACTR is overexpressed in several
breast and ovarian cancers (5). Though it is unclear if this is a cause or effect of
these cancers , it is possible that overexpression of ACTR leads to increased
activation of target genes which in turn may lead to increased cellular
proliferation. Additionally, the RNA polymerase III transcription factor TFIIIC2
which is an acetyltransferase , is overexpressed in ovarian tumors , contributing to
the abnormal abundance of pol III transcripts in these tumors (257).
2. Histone Deacetylation
While histone acetylation is associated with gene activation , histone
deacetylation is associated with gene repression. In fact, many gene products
that were known to act as corepressors were later found to have deacetylase
activity. The link between histone deacetylation and gene repression first was
demonstrated by the isolation of the human histone deacetylase HDAC1 , which
, ,
has sequence highly similar to the yeast Rpd3 , a known negative regulatory
protein (228). Histone deacetylases (HDACs) are categorized , based on
homology, into two classes. The first class includes the yeast HDACs Rpd3,
Hos1 , and Hos2 as well as the mammalian histone deacetylases HDAC1-3, and
9. The second class consists of yeast Hda1 and mammalian HDAC4- , and 10.
Most HDACs are associated in multisubunit complexes; substrate specificity is
regulated by components of these complexes.
The mammalian HDAC1 and HDAC2 have been shown to play important
roles in cellular growth arrest (46 , 118 , 147). The multiprotein complex SIN3-
HDAC consists of both HDAC1 and HDAC2 , along with the scaffolding protein
SIN3 and at least eight other proteins (3, 86, 162). This co-repressor complex
has been shown to associate with the basic helix-Ioop-helix-zipper protein Mad
and is required for Mad- induced transcriptional repression. The repression
mediated by this complex prevents the activation of target genes such as E2F
and cdc25, leading to growth arrest in a wide range of cells. HDAC activity
appears to be required for the ability of Mad to induce growth arrest , as inhibitors
of deacetylase activity partially overcome this effect.
The SIN3-HDAC complex also plays an important role in retinoblastoma
tumor suppressor protein (Rb)-mediated repression (reviewed in (80)). Rb
controls cellular proliferation by repressing transcription of genes required for
progression through G1 and S of the cell cycle. Rb is recruited to target genes
via its interaction with the E2F family of transcription factors. Rb represses E2F-
mediated transactivation by two mechanisms; it blocks the E2F transactivation
domain and it actively represses E2F promoters. The deacetylase activity of the
SIN3-HDAC complex helps to repress E2F-regulated genes.
Certain forms of leukemia are associated with misregulation of SIN3-
HDAC activity. RAR is a transcriptional regulator that responds to retinoids and
is important for the differentiation of cells into many lineages , especially myeloid
lineages (39). RARs recruit the SIN3-HDAC complex, via N-CoR (nuclear
receptor corepressor) or SMRT (silencing mediator for retinoid and thyroid
receptors), to promoters containing RARE (retinoic acid response element)
sequences. In the presence of retinoic acid (RA), the SIN3-HDAC complex is
released from RAR allowing the TIF2-CBP HAT complex to bind to a domain on
RAR that is masked in the absence of ligand (3, 86, 162 , 163). In this manner
retinoic acid is able to induce genes containing RARE sequences.
Chromosomal trans locations resulting in the fusion of the RAR gene to the
gene encoding PML have been associated with some cases of human acute
promyelocytic leukemia (APL) (71 , 137). The normal function of PML is unclear;
however, it is known to homodimerize and to interact with HDACs (153). PML-
RAR fusion proteins retain the regions of RAR required for DNA and ligand
binding, as well as the regions of PML required for HDAC interaction and
homodimerization. Leukemogenesis is believed to result from the dimerization of
the fusion proteins and subsequent stronger association with HDACs. HDAC
association is maintained at physiological levels of RA, but released at high
levels of ligand. Patients with PML- RAR translocations often go into remission
after treatment with pharmacological doses of retinoic acid. In other forms of
APL RAR is fused to PLZF (promyelocytic leukemia zinc finger) (71 , 137). The
normal function of PLZF is not known , though it is able to homodimerize and
interacts with SIN3-HDAC. The PLZF-RAR fusion protein retains these known
abiliies of PLZF. The SIN3 protein is not released from PLZF-RAR even at high
concentrations of RA , and patients with this translocation are resistant to
treatment with pharmacological does of retinoic acid. Interestingly, inhibitors of
histone deacetylase activity have been shown to dramatically potentiate retinoid-
induced gene activation of RA-sensitive and restore retinoid response of RA-
resistant APL cell lines (71 , 137). This finding suggests that the RAR fusion
proteins mediate leukemogenesis through aberrant chromatin acetylation.
3. Histone Methylation
Lysine histone methyltransferases contain a conserved methyltransferase
domain termed a SET (Su(var)3- , Enhancer-of-zeste , Trithorax) domain
(reviewed in (119, 200). To date , not all SET-domain containing proteins have
been shown to have methyltransferase activity, though lack of detectable activity
may be due to inappropriate assay conditions. The effect of histone methylation
on gene activation is varied. The lysine histone methyltransferases are divided
into four families: SUV39, SET1 , SET2 , and RIZ (119, 200).
The SUV39 subfamily includes: Suv39h1 , Suv39h2 , EuHMTase1 , G9a,
ESET, and CLLL8. Su(var)3-9 originally was identified in a genetic screen as a
suppressor of position effect variegation in Drosophila melanogaster. The SET
domain of Su(var)3-9 is the founding member of the SUV39 subfamily of SET
domains. The mouse homologues are Suv39h1 and Suv39h2 (186). Though
mice deficient for either gene are phenotypically normal , double knockout mice of
Suv39h1/h2display dramatic genomic instability (176). They are predisposed to
cancer and approximately one-third of the mice develops late-onset B-cell
lymphoma. A common feature of these tumors is non-segregated chromosomes
that are linked via acrocentric regions. These knockout mice have a greatly
reduced level of H3 K9 methylation , suggesting that the methyltransferase
activity of Suv39h1/h2 is important for suppressing tumorigenesis. The human
SUV39H1/2 methyltransferase has been linked to oncogenesis via its interaction
with Rb (167). This interaction is required for correct regulation of the gene
encoding cyclin E , which is important in cell cycle regulation (172). Many human
cancers have mutations in Rb and some of these Rb mutants fail to bind
SUV39H1 (167). It is possible that the interaction between Rb and SUV39H1
plays a significant role in tumor suppression.
The SET1 subfamily includes hSET7 and ySET1 , both of which have been
shown to possess a H3 K4-specific methyltransferase activity (191 , 249, 268).
Other members of this subfamily have not been shown to have methyltransferase
activity. These include the polycomb (PcG) proteins EZH1 and EZH2. Polycomb
genes are a group of genes required to repress homeotic (hox) gene activity.
MLL 1-3 and ALR , trithorax (trxG) genes that are required to maintain hox gene
activity, also belong to the SET1 subfamily. There are many links between
members of the SET1 subfamily and cancer. MLL 1 is translocated in many
leukemias (10, 275, 281). In fact, over 30 different chromosomal fusions of this
region have been observed and all of these fusions lack the SET domain.
Additionally, deletions in exon 8 of MLL 1 have been observed in acute
lymphoblastic leukemias (138). A partial duplication of MLL 1 has been
documented in acute myeloblastic leukemia and gastric carcinoma cell lines
(198). It is unclear if these mutations in MLL 1 result in tumorigenesis due to loss
of function of the normal MLL 1 product, a gain of function of the fusion proteins
or a combination of both. Another MLL gene product , MLL2 is amplified in some
solid tumor cell lines (93). Chromosomal aberrations of the third MLL gene
MLL3, are associated with hematological neoplasia and holoprosencephaly, a
congenital malformation of the brain and face (225). The polycomb gene EZH2
is upregulated in tumor cell lines (247). It is localized to a region crucial for
malignant myeloid disorders (35), and its SET domain interacts with XNP , which
is mutated in different inherent disorders , including ATR-X syndrome (36).
The SET2 subfamily includes NSD1- , HIF1 , AND ASH1. The founding
member of this subfamily, the S. cerevisiae SET2 protein , has intrinsic histone
methyltransferase activity specific for H3 K36 (217). Members of the mammalian
nuclear receptor-binding SET-domain containing (NSD) family contain a SET
domain that is highly related to that of ySET2; however, NSD proteins have yet to
be shown to possess methyltransferase activity. NSD1 can enhance androgen
receptor (AR)-mediated transactivation in prostate cancer, though it is unclear if
this is a cause or result of oncogenesis (254). In the t(5, 11 )(q35;p15.
translocation in acute myeloid leukemia NSD1 is fused to the NUP98 gene
which encodes a nucleoporin that plays a role in nuclear trafficking (100). In
addition , truncations in the SET domain of NSD1 have been identified in
individuals with Sotos syndrome , a familial disorder linked with a predisposition to
cancers such as Wilm s tumor, hepatocarcinomas , mixed paratoid tumors , and
osteochondromas (123). NSD2 maps to a region deleted in the Wolf-Hirschhorn
syndrome (WHS) critical region (212). Deletions in this region cause WHS
which is characterized by mental retardation and developmental defects. NSD2
often is found fused to the IgHgene in multiple myeloma (149, 212). The third
member of the NSD family, NSD3, is amplified in several breast cancer cell lines
and in primary breast carcinomas (211). In addition , this gene also is found
fused to NUP98 in acute myeloid leukemia (192).
The RIZ subfamily includes RIZ, BLlMP- , MEL 1 , PFM1 , and MDS1-EVI1.
The SET domain of the RIZ protein was the founding member of this subfamily.
None of the proteins in this subfamily have been shown to possess
methyltransferase activity. The RIZ gene encodes for two proteins , RIZ1 and
RIZ2 , via the use of two alternative promoters (1). RIZ2 is identical to RIZ1
except that it lacks the first 200 amino acids , including the SET domain. RIZ1
expression is reduced or lost in many types of cancer including breast cancer
lung cancer, osteosarcomas , hepatoma , neuroblastoma , and colorectal cancer
, 92). Frameshift mutations in RIZ have been found in 37% of primary tumors
of the colon , stomach , endometrium and pancreas (29, 183). Furthermore , mice
deficient for RIZ1 are prone to develop diffuse B-ceillymphomas and a broad
spectrum of unusual tumors (213). It is interesting to note that RIZ1-deficient
mice present with similar tumors as mice deficient for the Suv39h1/h2
methyltransferases. The MDS1-EVI1 gene encodes for two products: the SET-
domain-containing MDS1-EVI1 and the EVI1 protein that lacks the SET domain
(59). Certain chromosomal rearrangements cause disruption of the MDS-EVI1
protein and activation of the EVI1 protein leading to myeloid leukemia.
Furthermore , EVI1 is overexpressed in solid tumors and leukemia (59). Another
RIZ subfamily member BLlMP- is deleted in B-cell-non-Hodgkin lymphoma
(109, 157). MEL 1 is transcriptionally activated by translocation in acute myeloid
leukemia (156). Lastly, PFM1 maps to a tumor suppressor locus on
chromosome 12 (270).
Clearly, a large number of the SET-domain-containing proteins play an
important role in cell cycle regulation. In fact, misregulation of a number of these
proteins has been linked to a variety of cancers. In some cases , tumorigenesis
has been linked to the diminished methyltransferase activity of the disrupted
gene products. However, not all of the SET-domain proteins have been shown
to possess methyltransferase activity. As such , it is not clear if a
methyltransferase activity of all of the described factors is required for their
normal activity.
4. Histone Phosphorylation
The core histones and histone H1 undergo phosphorylation on specific
serine and threonine residues. Phosphorylation of H3 and H1 are cell cycle
regulated , with the highest level of phosphorylation occurring during M-phase
(68, , 175, 255). Phosphorylation of H1 has been associated with
transcriptional activation of the MMTV promoter (130). Phosphorylation of H3
also has been shown to playa role in the transcriptional induction of immediate
early genes in mammalian cells (38 , 148). H3 residues within the promoter of c-
fos and c-myc are rapidly phosphorylated in serum starved cells when the Ras-
mitogen activated protein kinase (MAPK) pathway is stimulated by growth
factors. Furthermore , the mitotic phosphorylation of H3 also is associated with
chromosomal condensation. The condensation of chromosomes during mitosis
is essential for the proper transmission of parental genetic information to
daughter cells. The aurora kinase family is involved in histone H3
phosphorylation (91). Members of the aurora kinase family are overexpressed in
a variety of cancers including colorectal cancers and invasive ductal carcinomas
of the breast (18, 226, 227 , 279). The mechanism by which overexpression of
aurora kinase family members leads to tumorigenesis is unclear; however, this
finding points to the importance of proper regulation of histone phosphorylation in
maintaining normal cellular proliferation.
5. Histone Ubiquitination
Histones H2A, H2B , H3, and the linker histone H1 can be reversibly
ubiquitinated. The carboxyl-terminus of the ubiquitin molecule is covalently
attached via an isopeptide bond to the e-amino group of lysine. Approximately
five to fifteen percent of total H2A and - 1 . 5% of total H2B present in mammalian
cells are monoubiquitinated (114 , 135 , 136, 256). Ligation of ubiquitin moieties
to short- lived proteins tags them for degradation by the 26S proteasome;
however, mono-ubiquitinated histones do not appear to be tagged for
degradation in vivo (201 264). The biological significance of histone
ubiquitination is unclear. Studies suggesting that ubiquitinated histone H2A is
associated with transcriptional activation are contrasted by those that suggest
ubiquitination of histone H2A result in gene repression (for review see (104)). 
date, only one tentative link between misregulation of histone ubiquitination and
cancer has been published. The levels of ubiquitinated H2A were found to be
highly upregulated in SV-40 transformed human fibroblasts and keratinocytes
suggesting that this modification may play an important role in cell cycle control
(242).
C. ATP-dependent Chromatin Remodeling
ATP-dependent chromatin remodeling complexes use the energy of ATP
hydrolysis to alter chromatin structure. Every ATP-dependent chromatin-
remodeling complex contains an ATPase subunit that is highly conserved across
species. Each of the ATPase subunits belongs to the SWI2/SNF2 superfamily of
proteins. Based on the homology of the ATPase subunit, these complexes can
be classified into three subfamilies: the SWI2/SNF2 subfamily; the ISWI
subfamily; and the CHD subfamily (Figure 1.2). While some attention is given to
each of these subfamilies , the bulk of discussion concentrates on SWI/SNF, the
focus of this thesis.
1. CHD Subfamily
CHD (!!hromo-helicase- NA-binding) proteins have a SWI2/SNF2- like
helicase/ATPase domain , a DNA-binding domain , and a chromodomain. This
subfamily includes S. cerevisiae Chd1 , human NURD complexes , Xenopus Mi-
complex, and Drosophila Mi-2 complex.
The yeast Chd1 has not been found to assemble into a complex , but
rather appears to dimerize (232). Chd1 has an ATPase activity that is stimulated
by DNA and nucleosomes. Chd1 is able to alter, to some extent, the DNase I
digestion pattern of in vitro assembled mononucleosomes. Yeast strains bearing
chd1-null deletions are viable; however, chd1-null mutants are synthetically lethal
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with swi2-null mutants, suggesting that Chd1 and SWI/SNF may share redundant
functions. In human cells , a complex possessing both ATP-dependent chromatin
remodeling activity and histone deacetylase activity was purified simultaneously
by three groups. These complexes were named NURD ( cleosome remodeling
and histone geacetylation), NuRD , and NRD ( cleosome remodeling and
geacetylating) (231 , 267 , 277). It is unclear whether these are identical
complexes or separate , highly related complexes. They contain one or both of
two human CHD proteins , CHD3/Mi-2a and/or CHD4/Mi- . CHD3/Mi-2 a and
CHD4/Mi- are highly related proteins that are autoantigens in
dermatomyositis , a human disease that predisposes 15-30% of those afflicted to
cancer (66 202). Recombinant Mi-2 protein was found to have ATPase activity
similar to that of intact NuRD complex (250). The histone deacetylase activity of
these complexes is provided by HDAC1 and HDAC2. These complexes also
contain either MTA1 or MTA2 ( e!astasis-,Sssociated protein), expression of
which correlates with the metastatic potential of several human cancer cell lines
and tissues (230). The NuRD complex has been shown to contain two
alternatively spliced forms of MBD3 (Methyl-CpG Binding Domain). Furthermore
this complex interacts with MBD2 , a protein that is believed to link NuRD to
methylated DNA MBD2 also has been identified as NY-CO- , a human cancer
antigen that is recognized by autoantibodies from some colon cancer patients
(248).
, ,,
2. ISWI Subfamily
Members of the ISWI subfamily contain a subunit that shares homology
with the Drosophila ISWI (Imitation Switch) protein. These subunits are
homologous to Swi2/Snf2 only in their ATPase domain. The ATPase activity is
stimulated by nucleosomal DNA
In Drosophila three ISWI-containing complexes have been identified:
NURF (nucleosome remodeling factor), CHRAC (chromatin accessibility
complex), and ACF (ATP-utilizing chromatin assembly and remodeling factor)
(98, 235 , 237 , 241). Aside from ISWI , the constituents of these complexes vary.
All share the ability to regularly space nucleosome arrays in an ATP-dependent
fashion; however, only CHRAC has been shown to increase the accessibility of
restriction enzymes to chromatin templates. Drosophila ISWI is essential for cell
viability. Interestingly, null and dominant-negative mutations in ISWI resulted in
alteration of the structure of the male X-chromosome , suggesting that this factor
plays a role in higher order chromatin structure (53).
Two homologues of Drosophila ISWI , Isw1 p and Isw2p, have been
identified in yeast cells (67 , 236). These two subunits are present in distinct
complexes. Like Drosophila ISWI , Isw1p and Isw2p possess an ATPase activity
thpt is stimulated by nucleosomal DNA. Isw1 p- and Isw2p-containing complexes
have an A TP-dependent nucleosome remodeling and spacing activity.
In humans , the Drosophila ISWI-homologue , hSnf2H , has been purified in
four, apparently distinct, complexes: RSF (remodeling and spacing factor),
WCRF , ACF , and hCHRAC (19, 133, 134 , 184). Like their homologues , these
complexes have an ATPase activity that is stimulated by nucleosomal DNA
Furthermore , they remodel and space nucleosomes in an ATP-dependent
manner. The RSF complex also has been shown to stimulate transcriptional
initiation from a promoter within a nucleosome template. The WCRF and ACF
complexes contain WSTF (Williams syndrome transcription factor) protein , which
has been found to be mutated in the developmental disorder Williams syndrome.
3. SWI2/SNF2 Subfamily
The SWI2/SNF2 subfamily includes S. cerevisiae SWI/SNF , RSC
(remodels the structure of chromatin), and IN080. com; Drosophila Brahma; and
mammalian SWI/SNF. The activity of the ATPase subunit of each of these
complexes is stimulated by both DNA and nucleosomes (31 56, , 124
182). The ATPase subunits also share a C-terminal bromodomain and two other
conserved regions of unknown function (260).
a. In080.com
The In080 protein was identified in yeast based on its homology to the
Swi2/Snf2 ATPase (207). In080 also has homologues in Drosophila (dIN080)
and humans (hIN080). The yeast In080 associates with approximately 12
proteins in a complex called In080.com. This complex possesses a 3' to 5' DNA
helicase activity, though it has yet to be determined if Ino.com is able to alter
chromatin structure. In080-null mutants are viable but are sensitive to
hydroxyurea, methyl methanesulfonate , ultraviolet light, and ionizing radiation
suggesting a role for In080.com in DNA damage response.
b. RSC Complex
The yeast RSC complex contains the ATPase Sth1 , a protein that shares
high homology with Swi2/Snf2 (31). This complex consists of 15 subunits , some
of which share homology with other members of the yeast SWI/SNF complex.
Rsc8/Swh3, Rsc6 , and Sfh1 are homologs to SWI/SNF subunits Swi3 , Swp73,
and Snf5, respectively. Unlike the yeast SWI/SNF constituents, members of the
RSC complex are required for mitotic growth (32). The RSC complex catalyzes
the transfer of histone octamers from one strand of DNA to another (142). It is
also able to increase the accessibilty of restriction nucleases to nucleosomal
templates (140). The remodeled state persists after removal of RSC and ATP
and can be reversed upon re-addition of RSC and A TP.
It is unclear if mammalian cells contain a complex homologous to yeast
RSC. The BAF180 subunit of the SWI/SNF-B complex shares homology with
three yeast RSC complex subunits , Rsc1 , Rsc2 , and Rsc4 (266). This has led
some to propose that SWI/SNF-B is the mammalian homologue of yeast RSC
(164). Furthermore , the mammalian SWI/SNF-B complex localizes to the
kinetochores of mitotic chromosomes , suggesting that this complex may playa
similar to RSC in cell cycle progression.
c. SWI/SNF complexes
The SWI/SNF complex first was identified in yeast (30 , 177). It is
comprised of 11 subunits , with the core ATPase subunit encoded by the
SWI2/SNF2 gene. None of the members of the yeast SWI/SNF complex are
required for viability; however, several of its components originally were isolated
as being required for mating type switching (SWI) and sucrose fermentation
(SNF) (23 , 165, 214). These phenotypes are due to the fact that SWI/SNF is
required for induction of the mating type switch gene, HO as well as the SUC2
invertase that is required for sucrose fermentation. The first hint that SWI/SNF
plays a role in chromatin remodeling came from the discovery that several
mutations that suppressed swi/snfphenotypes corresponded to genes encoding
histones and non-histone components of chromatin structure (89, 120, 121).
SWI/SNF later was shown to alter the DNase I digestion pattern of in vitro
assembled mononucleosomes , giving credence to the idea that it could directly
alter chromatin structure. In addition , the activity of SWI/SNF can faciltate the
binding of a number of transcription factors and accessibilty to restriction
nucleases to nucleosomal DNA templates (28 , 42 , 139, 239). Data obtained
from DNA microarray expression analysis indicate that approximately 5% of
yeast genes that are constitutively expressed are dependent on the ATPase
activity of SWI/SNF. Interestingly, SWI/SNF appears to be involved in the
repression of just as many genes as it activates (90, 222). Recently, SWI/SNF
was shown to directly repress transcription of the yeast gene SER3 (151).
Mammalian SWI/SNF complexes contain one of two SWI2/SNF2 ATPase
homologues , BRM (SNF2a) or BRG1 (SNF2f3) (252). The mammalian SWI/SNF
complex is composed of 8-12 subunits , with its composition differing slightly
between cell types. Like the yeast counterpart, mammalian SWI/SNF complexes
are able to disrupt the DNase I digestion pattern of in vitro assembled
mononucleosomes and increase the accessibiliy of some transcription factors to
nucleosomal templates (97 , 124).
The mechanism by which SWI/SNF alters chromatin structure is unclear.
There is data that have led some to suggest that SWI/SNF either removes or
rearranges the H2A-H2B dimers to facilitate remodeling (42 , 89, 131 , 144 , 178,
210). Other studies demonstrate that SWI/SNF is able to induce nucleosome
sliding or octamer transfer (103, 181). Lastly, experiments utilizing cross- linking
reagents demonstrate that the octamer need not be perturbed in order for
SWI/SNF to alter the DNase I cleavage pattern or restriction enzyme accessibility
of in vitro assembled mononucleosomes or arrays (6 , 22).
Components of mammalian SWI/SNF complexes have been implicated in
a variety of cellular processes. SWI/SNF complexes are involved in gene
activation events associated with nuclear hormone receptors , environmental
stress, and viral infection (2 , 13 40, 48, 159 174). Mammalian SWI/SNF
components also playa role in gene repression events; the repression of c-fos
and some E2F-regulated genes are mediated in part by SWI/SNF (161 , 233,
251). Furthermore , members of the SWI/SNF complex are targets of viral
regulatory proteins of Epstein-Barr virus , adenovirus , human papilloma virus , and
human immunodeficiency virus (HIV) (107 , 127 , 128, 154 , 262).
SWI/SNF complexes playa role in several developmental processes. The
induction of genes necessary for muscle differentiation in vitro require SWI/SNF
activity (49). Functional SWI/SNF complexes were shown to be required for the
alteration of chromatin structure , concomitant with muscle differentiation , in the
promoter region of myogenin , a muscle specific transcription factor required for
the differentiation process. Mouse knock-out experiments have demonstrated
that the SWI/SNF components Brg1 , Ini1 , and Srg3 play an essential role in
murine development, as mice homozygous-null for any of these factors are early
embryonic lethal (27 , 76 , 112 , 115 , 188).
SWI/SNF constituents associate with a number of known tumor
suppressors. Both BRG1 and BRM have been shown to interact with the Rb
tumor suppressor and facilitate the repression of certain gene expression events
required for entry into S-phase. In fact , BRG1 or BRM is required for Rb-
dependent G1 arrest (57 , 218, 276). SWI/SNF also has been shown to interact
with the breast cancer susceptibility gene product , BRCA1 (20). The ATPase
activity of BRG1 is required for the ability of BRCA 1 to stimulate p53-mediated
transcription , suggesting that SWI/SNF may function in recombination and repair
pathways. Ini1 also has been shown to interact with , and facilitate the function
, the growth arrest and DNA-damage inducible protein GADD34 , providing
another link between SWI/SNF and recombination and repair (263). Moreover
BRG1 and INI1 interact directly with the p53 tumor suppressor in co-
immunoprecipitation experiments (126). This interaction appears to facilitate
activation of some p53-responsive genes.
Misexpression of BRG 1 and BRM has been found in a number of human
tumor cell lines and primary tumors. Expression of BRG1 and BRM is down-
regulated or absent in tumor cell lines derived from various tissues, including
prostate , lung, and breast (259). In another study, both alleles of BRG1 were
found to be mutated in 2 out of 22 breast carcinoma cell lines examined (50). On
the contrary, BRG1 was found to be overexpressed in approximately 60% of
gastric carcinomas examined (203).
Results from mouse knock-out experiments reveal variable roles for Brg1
and Brm in tumorigenesis. Mice lacking Brm are viable but show mild
proliferative effects , suggesting a role for Brm in the control of cellular
proliferation (188). Mice lacking Brg1 are early embryonic lethal (27).
Furthermore , a small percentage of mice heterozygous for Brg1 develop
apocrine tumors. However, loss of heterozygosity in the tumors has yet to been
demonstrated.
SNF5/INI1 is a core subunit of all mammalian SWI/SNF complexes
purified to date (252). It originally was identified based on its homology to the
yeast Snf5 protein and by a yeast two-hybrid screen as a protein that interacts
with HIV-1 integrase ( INteg rase !nteractor 1) (107 , 158). Bi-allelic deletions or
truncating mutations of INI1 have been shown to be associated with most cases
of malignant rhabdoid tumor, a rare but aggressive pediatric cancer of the soft
tissues (16, 17 , 51 , 194 , 238, 245). Mutations in INI1 also have been found in
other neuronal tumors such as choroid plexus carcinomas , medullablastomas
and central primitive neuroectodermal tumors (15, 204). Furthermore , deletions
of INI1 have been reported in chronic phase and blast crisis of chronic myeloid
leukemia (69). Recent studies indicate that germ- line mutations in INI1
predispose afflicted individuals to some of these cancers (204 , 229).
Mice lacking Ini1 , like those lacking Brg1 , are early embryonic lethal (76,
115, 190). Approximately 30% of mice heterozygous for Ini1 develop
undifferentiated or poorly differentiated sarcomas , with variable rhabdoid
features , of soft tissues. In these cases , tumor occurrence has been correlated
with loss of heterozygosity at the Ini110cus. Furthermore , almost 100% of mice
bearing a reversibly inactivating conditional allele of Ini1 present rapidly with
tumors. While many of these tumors have variable rhabdoid features , the vast
majority are CD8+ T-cell lymphomas (189).
The INI1 protein has no known conserved motifs that may provide insight
into its function. While its exact function is not clear, INI1 is able to facilitate HIV
proviral DNA integration (107). INI1 also has been shown to repress expression
of cyclin 01 in INl1-deficient tumor cells to induce cell cycle arrest (278). Other
studies utilizing similar cell lines show that INI1 induces p16ink4a to induce cell
cycle arrest (14). INI1 has been shown to interact with ALL- , translocations of
which are involved in human acute leukemias (195). The Drosophila homolog of
ALL- , trithorax, likewise has been shown to interact with the INI1 homolog snr1.
Trithorax is a member of the trithorax-polycomb gene family that is required to
maintain proper expression of Antennapedia and Bithorax complexes throughout
embryogenesis (110). Like Ini1-null mice, homozygous snr1 mutants die early
during embryogenesis (54). These similarities between snr1 and INI1 hint at the
possibility that INI1 may playa role in homeotic gene regulation early in
mammalian development.
It is unclear if BRG1 and INI1 function independently as tumor
suppressors or function cooperatively via an activity of the SWI/SNF complex.
Heterozygous disruption of Brg1 and Ini1 in mouse models results in divergent
phenotypes. However, while disruption of Ini1 may affect both Brg1 and Brm-
containing complexes, it is possible that Brm is able to partially compensate for
Brg1-deficiency. Clearly, Brm is unable to compensate for the absence of Brg1
in early development. This may be due to the fact that during early mouse
embryonic development , Brg1 and Brm show differences in their levels of
expression as well as localization at the blastocyst stage (132). On the contrary,
the level of Brm message is comparable to that of Brg1 in adult tissues and many
cell lines. In human tumor cell lines lacking BRG1 , BRM is able to compensate
for BRG1 function in cell cycle arrest mediated by Rb (219). Thus , it is possible
that the presence of Brm in Brg1-heterozygous mice is sufficient to maintain the
putative tumor suppressor function of SWI/SNF.
While it is possible that the ability of BRG1 and INI1 to function as tumor
suppressors depends on their role in the SWI/SNF complex, recent data suggest
that INI1 has functions distinct from those of BRG1 and BRM. As mentioned
above , cell cycle arrest mediated by Rb depends on the presence of functional
BRG1 or BRM. On the contrary, INI1 is not required for the ability of Rb to
induce arrest (14 , 244). When a constitutively active Rb is introduced into human
tumor cell lines lacking INI1 , the cells arrest in G1. Therefore , it is possible that
the tumor suppressor function of Ini1 is distinct from its function as a member of
the SWI/SNF complex. However, before the biological roles of INI1 can be
compared to those of BRG1 or BRM , it is first necessary that the functions of INI1
be elucidated.
D. Thesis Aims
The focus of this thesis was the murine SWI/SNF subunit Ini1 , with
particular emphasis on its role in development and tumorigenesis. Chapter II
details the generation and characterization of a murine model deficient for Ini1.
The research described in this chapter demonstrated an essential role for Ini1 in
murine development , as mice null for Ini1 died early in embryogenesis.
Furthermore , mice heterozygous for Ini1 were predisposed to undifferentiated or
poorly differentiated tumors , suggesting that Ini1 also plays an important role in
tumor suppression.
Chapters III and IV present data aimed at understanding the mechanism
by which Ini1 functions as a tumor suppressor. As detailed above , Ini1 has been
linked to the tumor suppressors Rb and p53. Results from crosses of Ini1-
heterozygous mice to Rb-heterozygous mice (Chapter III) and p53-heterozygous
mice (Chapter IV) are described. We show that introduction of Ini1-
heterozygosity on a Rb-heterozygous background does not alter the tumor curve
from that observed for mice deficient solely for Rb. However, some of the tumors
that arose in compound heterozygous mice presented with histology
characteristic of more aggressive tumors. Mice heterozygous for Ini1 and p53,
however, showed a decreased rate of tumorigenesis compared to p53-
heterozgyous mice. In addition , the observed tumor spectrum was skewed.
In Chapter V , the regulation of Ini1 itself is examined. While Ini1 has been
shown to play an important role in a diverse set of processes , little has been
published as to its regulation. We show here that Ini1 is upregulated in cells and
tissues heterozygous for Ini1. This upregulation is mediated by an increase in
the rate of transcription from the Ini1 promoter, such that the steady level of Ini1
RNA from one allele in heterozygous cells approximately doubles that from wild-
type cells. Furthermore , we provide evidence suggesting that Ini1 is involved in
its own regulation.
Lastly, Chapter VI provides a brief discussion , with the aim of tying
together the sum of these results to provide a better understanding of the
regulation and function of Ini1.
Chapter II
Disruption of Ini1 Leads to Peri- Implantation Lethality and Tumorigenesis in Mice
Introduction
The compact nature of chromatin structure presents a barrier to cellular
processes that require access to DNA A number of multiprotein complex
have been identified that share the ability to modify chromatin structure. These
include the histone acetyl-transferases and deacetylases , complexes which
chemically modify the amino-terminal tails of histones by the addition or removal
of acetyl groups , respectively, as well as a group of enzymes that utilize the
energy derived from ATP-hydrolysis to alter nucleosome structure (96 , 113, 215,
216, 246). Included among these ATP-dependent chromatin remodeling
enzymes is the SWI/SNF family of chromatin modifiers.
SWI/SNF enzymes are large multisubunit enzymes of - 2 MDa. Yeast
SWI/SNF genes were originally identified as being required for mating type
switching or sucrose fermentation (23, 165, 214). Later work determined that
SWI/SNF genes were required for the induction of a subset of yeast genes and
that the SWI2/SNF2 protein possessed a DNA-stimulated ATPase activity (30,
117 125, 177 179 272). Mutations in SWI/SNF genes could be suppressed by
mutations altering histone gene expression , histone structure , or non-histone
chromatin proteins leading to the suggestion that these gene products facilitated
transcriptional activation by altering chromatin structure (89 , 120, 121).
1 .
Human SWI/SNF (hSWI/SNF) complexes contain either the human BRM
(hSNF2a) or BRG1 (hSNF2 ) homologues of the yeast SWI2/SNF2 ATPase (40,
111 , 159). Both yeast and human SWI/SNF complexes have been shown to
possess nucleosome remodeling activity in vitro (42 , 124). Components of
mammalian SWI/SNF complexes have been implicated in a variety of cellular
processes, including gene activation and repression , development and
differentiation , recombination and repair, and cell cycle control. There is
evidence supporting a role for SWI/SNF in gene activation events mediated by
nuclear hormone receptors , environmental stress , and viral infection (2 , 40, 48
, 159). In contrast, SWI/SNF components also were shown to be involved in
repression of c-fos and some E2F-regulated genes (161 233). Both BRG1 and
hBRM can interact with the retinoblastoma oncoprotein and induce cell cycle
arrest, an effect that is abrogated by the association of BRG1 with cyclin E (57
206 , 218 , 276). Evidence suggesting a role for hSWI/SNF in recombination and
repair was provided by studies demonstrating an interaction of components of
the hSWI/SNF complex with BRCA 1 which is thought to be involved in DNA
damage and repair pathways (20). Furthermore , members of the SWI/SNF
complex are targets of viral regulatory proteins upon infection of cells by
adenovirus , Epstein-Barr virus, human immunodeficiency virus , and human
papillomavirus (107 , 128, 154 261).
The role of SWI/SNF enzymes in whole organisms is unclear. While
homozygous disruption of Brg1 in mouse embryonic carcinoma cells resulted in
lethality, disruption of Brm expression in mice produced only mild proliferative
effects (188 , 223). The upregulation of Brg1 in the Brm-deficient mice may
provide a compensatory effect; however, one can not rule out the possibility that
these differences are due to distinct functions of Brm or Brg1-containing
complexes.
SNF5/INI1 is a member of both BRG1 and BRM-containing SWI/SNF
complexes (158 , 253). INI1 was shown to interact with ALL- , translocations of
which are associated with several types of human acute leukemias (195).
Furthermore IN/1 has been found to be altered in malignant rhabdoid tumors
choroid plexus carcinomas , medullablastomas , and central primitive
neuroectodermal tumors (17 , 51 , 204, 205, 245). Identification of constitutional
mutations in a subset of these tumors indicates that the INI1 is a tumor
suppressor (17 205). In an attempt to generate a mouse model that would allow
further characterization of the mechanisms of Ini1 in tumorigenesis as well as to
determine the role of the mammalian SWI/SNF complexes in development, we
generated mice deficient for Ini1 expression. We show that Ini1:deficient mice
die early in embryogenesis , likely due to an inability of the blastocysts to hatch
implant in the uterus, and continue development. In addition , we report that a
subset of the Ini1- heterozygous mice present with a variety of tumors in the soft
tissues of the head and neck and that loss of heterozygosity at the Ini1locus 
correlated with tumor formation.
Materials and Methods
Ini1 targeting
ES cells (omnibank # OST32815) bearing a retroviral promoter trap that
functionally inactivates one allele of Ini1 were generated as described previously
(274). RACE analysis also is described. Site of insertion was determined using
sequence analysis.
Creation of Ini1-null mice
Ini1- targeted ES cells were injected into 3.5 d. c. C57BU6 blastocysts.
Male chimeric mice were mated with wild-type C57BU6 or 129 females.
Germline transmission of the mutant allele was determined by PCR analysis of
tail genomic DNA using the following primers: for Ini1 , 5'
GCAAGCGCTCTGCCAA TTG ACC- , 3' CACACCCT ATTGTCACTCTGGAA-
for pgeo CGGTATCGATA AGCTTGATGATC- , 3'
GTCAACGCGTCGGACTTACCGC- Ini1- heterozygous mice were intercrossed
to generate Ini1-null mice. Embryos 6.5 d. c. and younger were prepared for
genotyping by PCR as described previously(88). Nested PCR was done using
the above primers for the first round of PCR (29 cycles) and the following intron
3-nested primers for the second round (29 cycles): 5'
GCGTGCGCCACCATGCCTGG- , 3' CTTCTGGAGACTTCACTT AC GTCC-
Blastocyst culture
Blastocysts from heterozygous intercrosses were flushed from the uterus
of Ini1 in3 females 5 d. c. with M15 media (DMEM , 15% fetal calf serum , 100
JlM -mercaptoethanol , 2 mM glutamine , and 1 X penicillin/streptomycin) and
cultured in tissue culture plates for 96 hr. Embryo cultures were genotyped 
described above.
Galactosidase staining of cultured ES cells
Wild-type AB2. 2 ES cells and Ini1 in3
/+ 
ES cells were grown to near
confluency and fixed in 0.5% Glutaraldehyde. Cells were then rinsed with PBS
and stained overnight in the dark at room temperature in a solution containing
5mM Potassium Ferricyanide , 5mM Potassium Ferrocyanide , 2mM MgCI , and
1 mg/ml X-gal.
Whole mount staining of embryos for galactosidase activity
Embryos were harvested at indicated time points post fertilzation and
fixed in 4% paraformaldehyde for 20 min at 4 C. Embryos were washed and
then stained in X-gal histochemical reaction mix (4mM Potassium Ferrocyanide
4mM Potassium Ferricyanide , 2mM MgCI , 1 mg/ml X-gal) overnight at room
temperature. Following staining, embryos were rinsed in PBS and cleared in
30% sucrose.
Western analysis of tumor samples
Control tissues and tumor samples were homogenized in lysis buffer
containing 50 mM tris-HCI , pH 7. 150 mM NaCI , 0.5% NP- , 20% glycerol , 1
mM DTT, 1 J.g/mL pepstatin A , 4 J.g/mL leupeptin , and 1 mM PMSF. Extracts
were resolved by SDS-PAGE and western analysis for Ini1 protein was
performed as described previously(48).
Histologic analysis of tumors in mice
Tumor samples and selected tissues were fixed in 10% buffered formalin
phosphate and processed for paraffin embedding as described previously(81).
Sections were prepared and stained with haematoxylin and eosin and examined
under a microscope.
Results and Discussion
Mouse embryonic stem (ES) cells bearing a retroviral promoter trap that
functionally inactivates one allele of Ini1 were constructed as described
previously (274). Sequence analysis revealed that the promoter trap inserted
within intron 3 of Ini1 (Figure 2. 1). The beta-galactosidase-neomycin (f3-geo)
gene fusion cassette within the retroviral insertion has a 5' splice acceptor site;
thus f3-geo expression is regulated by the native Ini1 promoter. We were able to
utilze the f3-geo gene cassette in a colorimetric assay to determine if Ini1 
retroviral
trap
PGK-Puro
Figure 2.1: Schematic of targeted Ini1 allele
sa and sd represent splice acceptor and splice donator sites, respectively
TR(del) are the retrovirallong terminal repeat promoters with inactivating deletions
gal/neo is a galactosidase/neomycin gene fusion cassette
PGK-puro is a puromycin cassette under control of a PGK promoter
carets denote site of alternative splicing within the Ini1 gene
normally expressed in ES cells. Ini1- targeted cells stained positive for /3-gal
activity, indicating that Ini1 is expressed in ES cells (Figure 2.2). Northern
analysis of ES cell total RNA confirmed Ini1 expression (data not shown).
Furthermore , sequence data obtained from 5' RACE analysis of the Ini1-/3-gal
fusion mRNA revealed that transcripts utilizing either splice donor site in exon 2
spliced into the trap, indicating that both splice variants of Ini1 were inactivated
(26).
To determine the role of Ini1 in mammalian development and
tumorigenesis , we used the targeted ES cells in blastocyst injection experiments
to generate Ini1-heterozygous (Ini1 in3 mice. In order to monitor expression of
Ini1 during embryogenesis , we performed whole mount staining for /3-
galactosidase activity in embryos harvested from Ini1 in3l matings at various times
during development. We found that Ini1in3
/+ 
embryos stained positive in all
tissues at all time points examined , including 6.5, 8.5, 9. , and 10.5 d.
indicating that Ini1 is ubiquitously expressed during embryogenesis (Figure 2.3).
Ini1 expression was also detected by northern analysis in a wide range of adult
tissues (188) (and data not shown).
Chimeric mice generated from C57BU6 strain blastocyst injections of the
129 strain-derived ES cells were bred to wild-type C57BU6 or 129 mice in order
to obtain Ini1 in3
/+ 
mice on either a mixed (C57BU6 x 129) or pure (129)
background. Intercrosses of Ini1 in3
/+ 
mice in both backgrounds yielded Ini1 in3
offspring and wild-type offspring at a 2: 1 ratio (63:26 in the mixed background
'o'
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Figure 2.2: Mouse embryonic stem (ES) cells expres Ini1
Wild-type and Ini1-targeted ES cells were stained for f3gal activity. Because
l3-gal is under control of the Ini1 promoter, cells that express fni1 wil stain
blue.
......
d6.
d9.
Figure 2.3: Ini1 is ubiquitously expressed throughout embryonic
development
Embryos from Ini1-heterozgyote intercrosses were harvested at indicated
times and stained for I3gal activity. Targeted cells wil stain blue, while
wild-type cells wil not.
34:17 in the pure background), and no Ini1-null offspring, indicating that
disruption of Ini1 induces embryonic lethality (Figure 2.4). Timed matings of
Ini1 in3
/+ 
mice were performed and embryos harvested at various time points in
gestation for genotyping via PCR. Ini1-null embryos could be isolated at 3.
c. and were normal in appearance. However, no Ini1 in3/in3 embryos were
detected at 6.5 d. c. or later (Figure 2.5). Dissection of maternal diciduas at 6.
5 d. c. revealed no significant increase in the number of embryo
reabsorptions , suggesting that Ini1 in3/in3 lethality occurred between day 3.5 and
5 of gestation. These results indicate that Ini1-null embryos either failed to
implant into the uterine wall or implanted and were reabsorbed shortly thereafter.
In order to examine further the developmental defect of Ini1 in3/in3 embryos , we
analyzed the ability of blastocysts from Ini1 in3
/+ 
intercrosses to expand in vitro.
When 3.5 d. c. blastocysts were plated in culture , wild-type and Ini1 in3
blastocysts hatched from the zona pellucida and implanted onto the tissue
culture plastic. Both wild-type and Ini1 in3 implanted embryos formed
trophectoderm and expanded their inner cell mass (ICM). In contrast, no
Ini1 in3/in3 blastocysts hatched and implanted in culture (Figures 2.5 and 2.6). The
results of these experiments suggest that the peri-implantation embryonic
lethality of Ini1-null mice may be due to a defect in hatching of the blastocyst
from the zona pellucida , an obligate step for implantation of the embryo into the
wall of the uterus during normal development. Manual disruption of the zona
targeted
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Figure 2.4: Ini1-null mice are embryonic lethal
Ini1- heterzygous mice were intercrossed and progeny genotyped
by PCR. As shown above theWT allele generates a 700 bp band
while the targeted allele generates a 250 bp band. No Ini1-null
mice were obtained from these crosses.
targeted
+/-
p.f.
+/+ +/-
in vitro (dead)
13.
Figure 2. 5: Ini1-null embryos die between days 4 and 5.5 post-
ferti I ization
Embryos from InH- heterozygote intercrosses were harvested at
indicated times and genoyped by PCR. While Ini1-null embryos were
obtained at day 3.5 post-fertilization , no Ini1-null embryos were obtained
at day 6.5 and beyond.
+/++/-
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Figure 6: Ini1-null blastocysts fail to expand in culture
Blastocysts were harvested from Ini1- heterozygote intercrosses at 3.5 days post
fertilization and plated in culture as described in the materials and methods. 
96 hours after culturing, outgrowths were harvested and genotyped by PCR.
Unlike their wild-type and Ini1-heterozygous counterpart, Ini1-null blastocysts
failed to attach to the substratum , form trophectoderm, and expand their inner
cell mass.
pellucida of 19 (C57BU6 x 129) blastocysts harvested from Ini1 in3
/+ 
intercrosses
did not result in expansion of Ini1-null trophectoderm or ICM during in vitro
culture , suggesting that growth of these tissues also is compromised (Figure 2.7).
Expression of Ini1 in ES cells , which are derived from the ICM of 3.5 d.
blastocysts , is consistent with a gene crucial to the peri- or pre- implantation stage
of embryogenesis.
In humans , loss of INI1 is correlated with a variety of tumors , the vast
majority of which are neuronal or renal in nature. To date , most human
malignant rhabdoid tumors and choroid plexus carcinomas examined have
deletions and/or mutations in INI1 as do a subset of central primitive
neuroectodermal tumors and medullablastomas (204). In mice , we found that
approximately 20% of Ini1 heterozygotes in both the mixed F1 (C57BU6 x 129)
or pure 129 backgrounds presented with tumors (Figure 2.8). All of these tumors
arose in the head or neck region of the mice , particularly in the soft tissue of the
face (Figure 2.9). While 2 of the 15 mouse tumors analyzed had varying degrees
of rhabdoid- like cells , characterized by their eosinophilic cytoplasms containing
speroid perinuclear inclusion bodies and whorls of intermediate filaments , none
had the monomorphous appearance of human rhabdoid tumors. Two Ini1 in3
mice were found to have a Iymphoproliferative disorder or lymphoma originating
in an ill-defined region on the neck (Table 2. 1 and Figure 2. 10). Two-thirds of the
tumors originated on the face of the mice. Interestingly, expression of Ini1
appears to be elevated during development in the branchial arch and in the
Figure 7: Ini1-null blastocysts fail to expand in culture when
manually hatched
Ini1-heterozygous mice were intercrosses and blastocysts harvested at
day 3.5 post-fertilzation. Blastocysts were plated in culture and zona
pellucidas were removed manually with a fine-pulled needle. After 96
hours in culture, outgrowths were harvested and genotyped by PCR.
, trophectoderm; ICM , inner cell mass
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Figure 2.8: Tumor Curve for Ini1..heterozygous mice
Ini1-heterozygous mice on both a purebred and mixed background were
monitored for tumor development. Mice presenting with tumors were graphed
accrding to age in weeks.
Figure 2.9: Ini1-heterozygous mice present with tumors mostly in the
head and neck region
Photograph of Ini1-heterozygous mouse presenting with facial tumor common
in this study.
Table 1: Tumor Occurrence
Mouse Age (weeks) Tumor Site Classification
Ini 119 face undifferentiated sarcoma
Ini 44 face undifferentiated sarcoma
Ini 138 face malignant fibrous histiocytoma
Ini 100 face malignant fibrous histiocytoma
Ini 180 face undifferentiated sarcoma
Ini 26* face malignant fibrous histiocytoma
Ini 262 face malignant fibrous histiocytoma
Ini 29* face malignant fibrous histiocytoma
Ini 13* face/eye liposarcoma
Ini 56 neck lymphoma
Ini 322 brain undifferentiated sarcoma
Ini 10 ventral to brain undifferentiated sarcoma
Ini 95* face malignant fibrous histiocytoma
Ini 127 neck Iymphoproliferative disorder
Ini 328 eye undifferentiated sarcoma
129 Strain
Table 2.1: Representation of tumors from Ini1-heterozygous mice
Figure 
Figure 2. 10: Tumor sections from Ini1-heterozyous mice
Tumor samples were harvested from mice and processed for H&E
staining as described in the materials and methods. Most tumors were poorly
differentiated or undifferentiated sarcomas with the exception of one liposarcoma
(panel 13) and one lymphoma (panel 56). Some tumors show variable rhabdoid
features (see arrow in panel 119). Numbers in figure correspond to mice listed in
Table 2.
frontonasal and maxillary processes (Figure 2.3), structures that contribute to
formation of the face. While the majority of the facial tumors were poorly
differentiated or undifferentiated sarcomas and not neuronal in origin , it is
possible that the tumors arose in cells derived from neural crest progenitors , as
neural crest cells , along with mesodermal cells , coordinate to form the facial
primordia (63, 199).
We have analyzed tumors in three representative mice. Northern analysis
of total RNA harvested from tumor tissue indicated the presence of wild-type-
length Ini1 message (data not shown). However, western blot analysis of
proteins harvested from these tumors revealed absence of Ini1 protein in all three
samples (Figure 2. 11). This indicates that LOH at the Ini110cus is responsible
for tumor formation in the Ini1 in3
/+ 
mice.
The mechanism of Ini1-mediated tumor suppression is unclear. Other
subunits of the Swi/Snf chromatin remodeling complex have been reported to
associate with known tumor suppressors , including Rb and Brca1 (20, 233,
276), and several of the SWI/SNF subunits appear to be molecular targets of
viral regulators of cell proliferation (107 , 128, 154, 261). In addition , one of these
subunits , BRG1 , recently has been reported to be missing or mutated in a variety
of human tumor cell lines , and reintroduction of BRG1 into these tumor cells
reverses their transformed morphology (259). These findings suggest a role for
chromatin remodeling in regulation of cell growth and/or in tumor suppression.
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Figure 2.11: Tumors from In;1-heterolygous mice show los of
heterozygosity
Tumor samples and control tissue were processed for Western
analysis as described in the materials and methods. As shown
above, tumor samples show a marked decrease in expression of Ini1
protein compared to wild-type brain, indicating loss of heterozygosity.
, non-specific band
While this manuscript was in preparation , Roberts et al. and Klochendler-
Yeivin et al. published data consistent with our findings (115, 190). The fact that
these results are reproducible in knock-out lines generated by different targeting
strategies confirms the importance of Ini1 in development and tumorigenesis.
Klochendler- Yeivin et al. further report in their study that Ini1-deficient embryos
can induce the formation of maternal dicidua, suggesting that Ini1-deficient
embryos undergo hatching and implantation prior to their demise. In contrast
Ini1 in3/in3 embryos fail to hatch from the zona pellucida , suggesting that subtle
strain variations may influence the precise timing of embryonic lethality. In
agreement with these other groups , a percentage of the Ini1 heterozygous mice
in our colony presented with tumors that contained variable numbers of rhabdoid
cells. However, we are hesitant to classify these undifferentiated sarcomas as
true rhabdoid tumors , which are described as monomorphous tumors in the
human population. Discrepancies between tumor types associated with
disruption of Ini1 in humans and mice may be due to differences in species-
specific differentiation pathways. Regardless , the Ini1 heterozygous mice should
provide a useful model for studying the general mechanisms involved in tumor
suppression by Ini1.
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Chapter II
Disruption of Ini1 on a Rb-heterozygous Background in Mice Alters Tumor
Morphology but Not Tumor Rate
Introduction
INI1 functions as a tumor suppressor in humans and mice. It originally
was identified in mammals based on its homology to the yeast Snf5 protein as
well as via a yeast two hybrid assay as a protein that interacts with the HIV
integrase protein (107 158). INI1 is a member of all SWI/SNF chromatin
remodeling enzymes purified to date (252). The identification of bi-allelic
mutations in INI1 in malignant rhabdoid tumors , an aggressive tumor of the soft
tissues , provided the first evidence that INI1 plays a role as a tumor suppressor
(245). Mutations in INI1 were found subsequently in other tumors , such as
choroid plexus carcinomas , medullablastomas , central primitive neuroectodermal
tumors , and a few cases of leukemia (15- 69, 205). The fact that a subset of
patients presenting with these tumors had constitutional mutations further
supported the role of INI1 as a tumor suppressor in humans (17 , 205).
Gene targeting experiments confirmed that Ini1 also functions as a tumor
suppressor in mice (76 , 115 , 190). While Ini1-null mice are embryonic lethal , 15-
30% of mice heterozygous for Ini1 present with tumors , all of which are poorly
differentiated or undifferentiated tumors with variable rhabdoid features. All
tumors examined show loss of heterozygosity at the Ini110cus. Furthermore
almost 100% of mice bearing a reversibly inactivating conditional allele of Ini1
present rapidly with tumors. While many of these tumors have variable rhabdoid
features , the vast majority are CD8+ T-cell lymphomas (189).
Despite the fact that INI1 plays a role in tumor suppression , the
mechanism by which it does so has yet to be elucidated. BRG1 and BRM
ATPases that constitute biochemically distinct SWI/SNF complexes , both playa
role in growth arrest mediated by the retinoblastoma (Rb) tumor suppressor (57
218 , 276). When Rb is hypophosphorylated (active), it is bound by the histone
deacetylase HDAC1and BRG1/BRM , thereby repressing E2F activity (276). E2F
is a transcription factor responsible for inducing the expression of a number of
genes required for DNA synthesis , such as ribonucleotide reductase
topoisomerase II , DNase polymerase ex, and proliferating cell nuclear antigen
(PCNA) (52). At the onset of S-phase , coordinated phosphorylation events result
in the release of HDAC1 and BRG1/BRM , allowing for the activation of E2F and
progression through S-phase.
Unlike wild-type cells , SW13 cells derived from an aprocine tumor lacking
BRG1 and BRM do not arrest when a constitutively active form of Rb is
introduced (220). Furthermore , a constitutively active form of Rb is not able to
arrest 3T3 mouse fibroblasts that express an ATPase-defective BRG1 (221).
These data suggest that functional SWI/SNF is required for Rb-mediated arrest.
Like BRG1 and BRM , the ability of INI1 to arrest cells depends on the presence
of functional Rb (244). However, a constitutively active form of Rb is able to
arrest a variety of INl1-deficient cell lines derived from malignant rhabdoid
tumors. It is unclear if the observed difference in Rb activity is due specifically to
absence of INI1 versus BRG1/BRM , or if other differences between the various
cell lines utilized may be responsible.
To determine if Rb participates in INl1-mediated tumor suppression , we
crossed Ini1- heterozygous mice to Rb-heterozygous mice and monitored the
offspring for tumor formation. We found that the tumor curve for mice
heterozygous for both Rb and Ini1 was virtually indistinguishable from that for
Rb-heterozygous mice. Like Rb-heterozygous mice , almost all of the compound
heterozygous mice succumbed to pituitary adenomas. However, approximately
one half of the tumors from the compound heterozygous mice had an atypical
histology. These data suggest that loss of Ini1 may contribute to the
aggressiveness of pituitary adenomas associated with loss of Rb.
Materials and Methods
Mouse strains
Ini1- heterozygous mice on a mixed (C57/BI6 X 129) background and Rb-
heterozygous mice were described previously (76, 129). Tail DNA from mice
was genotyped for Ini1 as described. Rb genotyping was done by PCR using the
following primers: 5'aattgcggccgcatctgcatcatctttatcgc , 5'cccatgttcggtcctag, and
gaagaacgagatcagcag. An annealing temperature of 53 C was used.
Histologic analysis of tumors in mice
Mice were sacrificed when they presented with visible tumors or signs of
wasting. Tumor samples and selected tissues were fixed in 10% buffered
formalin phosphate and processed for paraffin embedding as described
previously (81). Sections were prepared and stained with haematoxylin and
eosin and examined under a microscope.
Results and Discussion
We previously described the generation and characterization of Ini1-
heterozygous mice (76). These Ini1- heterozygous mice were mated to Rb-
heterozygous mice (described in (129)) and compound heterozygous progeny
were intercrossed. Resultant progeny were genotyped for Ini1 and Rb. No Ini1-
null or Rb-null mice were obtained (Table 3.1), regardless of the genetic
background , indicating that loss of Rb does not rescue lethality due to absence of
Ini1 and vice-versa.
Because Ini1-null and Rb-null mice are embryonic lethal (77, 131), only
four Ini1/Rb genotypes were available for tumor analysis: wild-type
(Ini1+/+Rb+/+), Rb-heterozygous (Ini1+/+Rb+/-), Ini1-heterozgyous (Ini1+/-
Rb+/+), and compound heterozygous (Ini1+/-Rb+/-). As reported previously (77),
wild-type mice did not present with tumors during the course of this study. Also
described previously (131), all mice heterozygous for Rb and wild-type for Ini1
presented with pituitary adenomas by 80 weeks of age. Furthermore
Genotype Expected Actual
Ini1 +/+Rb+/+
Ini1 +/+Rb+/-
Ini1 +/+Rb-
Ini1 +/-Rb+/+
Ini1 +/-Rb+/-
Ini1 +/-Rb-
Ini1- Rb+/+
Ini1- Rb+/-
Ini1- Rb-
Table 3. 1: Absence of Rb does not rescue In;1-null embryonic
lethality and vice-versa
Mice compound heterozygous for Ini1 and Rb were intercrossed
and their progeny were genotyped as described in materials and
methods. As shown , no Ini1-null or Rb-null mice were obtained.
approximately 20% of mice heterozygous for Ini1 and wild-type for Rb presented
with poorly differentiated or undifferentiated sarcomas with variable rhabdoid
features. These tumors were described in our previous study (77). Interestingly,
the tumor curve for Ini1+/-Rb+/- mice was similar to that observed for Rb+/- mice
(Figure 3. 1). The vast majority of the compound heterozygous mice (24 of 25)
presented with tumors by 80 weeks of age. Most of these tumors were pituitary
adenomas , with the exception of one tumor, which presented in the neck (Table
2 and data not shown).
Upon histological analysis of a number of the tumors from Ini1+/-Rb+/-
mice , it became clear there were morphological differences from the typical
pituitary adenomas that Rb+/- mice develop. All of the 12 pituitary adenomas
examined from Ini1 +/+Rb+/- mice had a histology that was uniform in
appearance (Figure 3.2). The tumor cells were small with centric nuclei and an
apparently low mitotic index. While many of the pituitary adenomas from the
Ini1+/-Rb+/- mice were indistinguishable from those from Rb+/- mice,
approximately one half (8 of 15 analyzed) of the tumors from the Ini1+/-Rb+/-
presented with an altered phenotype. As shown in Figure 3. , these tumors had
a less uniform appearance. There were many large cells with acentric nuclei. In
addition , the gross mitotic index appeared higher than tumors from the Rb+/-
counterparts. Often , these tumors appeared to have 2-3 different populations
cells: one population that resembled a typical pituitary adenoma and one or more
with an atypical histology.
Rb+/-
Rb+/- lni1 +1 (n=25)
Ini1 +/-
Age (weeks)
Figure 3. 1: Heterozygosity of In;1 does not alter tumor curve of Rb-
heterozygous mice
Survival curve for Ini1+/-Rb+/- mice was generated during this study. Tumor
curve for Ini1 was described previsouly (77). Data for Rb+/- mice of same
strain as compound heterozygous mice were provided by Andrew Koff.
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Mouse Age Tumor Characterization
(weeks)
RI133e 104 c/w pituitary adenoma
R255 c/w necrotic pituitary adenoma
R214 cellular poorly differentiated malignant tumor (malignant
pituitary adenoma)
R235 probable pituitary adenoma with foci of atypical or
malignant histology (i nuclear size , pleomorphism
apoptotic cells, mitoses)
R212 c/w pituitary adenoma with slightly atypical histology
(pleomorphism , apoptotic cells)
RI24 pituitary adenoma, and 2) malignant tumor with foci of large
tumor cells with rhabdoid features
RI112e probable pituitary adenoma with focally atypical or
malignant histology
R210 c/w pituitary adenoma
RI18 small aggregates of tumor cells with slightly atypical
histology
RI1 c/w pituitary adenoma
RI25 c/w necrotic pituitary adenoma
Table 2: Representation of tumors from Ini1 +/-Rb+/- mice
Tumors showing atypical morphology are noted
Figure 3.2: Approximately one half of pituitary adenomas from Ini1+/-
Rb+/- mice have an altered morphology
Tumor samples from Ini1 +/-Rb+/- mice were processed for H&E staining as
described in the materials and methods. H&E stained tumor slides for Rb+/-
mice were provided by Andrew Koff. Arrows denote large, rhabdoid-like cells.
We were interested in determining the state of Ini1 in these atypical tumors. 
has been well documented that pituitary adenomas from Rb+/- mice show loss of
heterozygosity at the Rb locus (131 , 175); therefore, loss of Rb alone could not
account for the altered phenotype in the tumors from the compound
heterozygous mice. To date , no pituitary adenomas have been described in
Ini1+/- mice. One possibility is that the pituitary tumors arose when the wild-type
Rb allele was lost and the subsequent loss of Ini1 in some of the tumors resulted
in the development of a distinct tumor type. To determine if the more aggressive
population of tumor cells arose due to loss Ini1 , we are in the process of doing
immunohistochemistry for Ini1 in the atypical tumors.
Discussion
Rb and Ini1 are tumor suppressors required for viability and prevention of
oncogenesis. While Rb and Ini1 have been linked to cell cycle arrest via the
SWI/SNF chromatin remodeling complex , the direct interactions between Ini1
and Rb are less clear. Functional BRG1 is required for the ability of a
constitutively active form of Rb to arrest cells; however, INI1 is dispensable for
this function of Rb (218, 244). On the contrary, the ability of INI1 to arrest cells is
dependent on the presence of functional Rb. These data present conflicting
conclusions as to whether or not Rb and Ini1 are functionally linked. In an
attempt to discern the biological significance of any potential interactions
between these two tumor suppressors , we crossed Ini1- heterozygous and Rb-
heterozygous mice. As mice homozygous null for Ini1 or Rb are embryonic
lethal , we were able to characterize tumor progression only in the compound
heterozygous mice.
Mice that are deficient for Rb and either p27 or p53 , two tumor
suppressors that are on intersecting pathways with Rb , develop tumors at a
faster rate than mice deficient for either tumor suppressor alone (82 , 173). We
report here that the tumor rate in mice heterozygous for both Rb and Ini1 was
unaltered from that for Rb-heterozygous mice. This finding suggests that neither
Rb nor Ini1 require the other to mediate tumor suppression.
Interestingly, approximately one half of the pituitary adenomas that
develop in the Ini1+/-Rb+/- mice have a morphology that is uncharacteristic of
those that normally develop in Rb+/- mice. As mentioned above , these tumors
appear to have two to three subpopulations of cell types. At least one population
is similar to that which is seen in typical pituitary adenomas. In contrast, the
other population(s) has a morphology that is similar in appearance to tumors that
develop in Inn- heterozygous mice. Specifically, large cells reminiscent of
rhabdoid cells are visible in these tumors (Figure 3. , arrow).
To date , we have yet to identify any pituitary adenomas from Rb-
heterozygous mice that have an altered morphology similar to that described for
some of the tumors that arose in Ini1 +/-Rb+/- mice. Furthermore , we never
observed any pituitary tumors , or neuronal tumors , in mice heterozygous for only
Ini1. Therefore , it is likely that Rb and Ini1 are both disrupted in the altered
pituitary adenomas. We are currently trying to determine if Ini1 is indeed lost in
these tumors.
The significance of the altered morphology of the pituitary adenomas in
Ini1+/-Rb+/- mice is unclear. While their non-uniform morphology suggests that
these tumors are more aggressive, there is no correlation in this study between
tumor morphology and the age of the mouse at the time of sacrifice. Of course
as it is not feasible to visually monitor progression of these tumors , it is possible
that they proliferated more quickly after developing the altered morphology. It will
be interesting to determine if any of the tumor cells lost Ini1 expression and
whether or not absence of Ini1 expression correlates with morphology.
Regardless , though absence of both Ini1 and Rb does not appear to accelerate
tumorigenesis , Ini1 does contribute to the tumor morphology associated with loss
of Rb.
As mentioned above , BRG1 is required for the ability of Rb to growth
arrest cells. Brg1-null mice are early embryonic lethal; however, a small
percentage of mice heterozygous for Brg1 present with tumors (27). It would be
interesting to determine if loss of Brg1 alters the rate of tumorigenesis in Rir
heterozygous mice. Such experiments may determine if Ini1 functions
independently of SWI/SNF.
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Chapter IV
Heterozygosity at the Ini1 Locus Inhibits Tumor Formation in p53-heterozygous
Mice and Alters Tumor Spectrum
Introduction
INI1 is a component of all SWI/SNF chromatin remodeling enzymes
purified to date. It originally was identified in mammals based on its homology to
the yeast Snf5 protein as well as via a yeast two hybrid assay as a protein that
interacts with the HIV integrase protein (107 158). INI1 has been well
established as a tumor suppressor in humans and mice. INI1 is mutated in a
number of human tumors , including rhabdoid tumors, choroid plexus carcinomas
medullablastomas , central primitive neuroectodermal tumors , and a few cases of
leukemia (15- 69, 205). Furthermore , constitutional mutations in INI1 have
been identified in some of these tumors (17 , 205).
Ini1 also functions as a tumor suppressor in mice (76, 115, 190). While
Ini1-null mice are embryonic lethal , 15-30% of mice heterozygous for Ini1 present
with tumors , all of which are poorly differentiated or undifferentiated tumors with
variable rhabdoid features. All tumors examined show loss of heterozygosity at
the Ini110cus. Furthermore , almost 100% of mice bearing a reversibly
inactivating conditional allele of Inn present rapidly with tumors. While many of
these tumors have variable rhabdoid features , the vast majority are CD8+ T-cell
lymphomas (189).
While it is apparent that INI1 is a potent tumor suppressor, the mechanism
by which it exerts its effect is unclear. The p53 tumor suppressor is one of the
most studied transcription factors to date. It is mutated or deleted in a wide
variety of human tumors , including those of the head and neck (143).
Interestingly, most of the tumors that present in Ini1- heterozygous do so in the
head and neck region. Furthermore , Ini1 has been linked indirectly to p53 via the
SWI/SNF complex , which has been shown to co-purify from human cells with the
breast cancer susceptibility protein BRCA1 (20). An ATPase-active BRG1 is
required for the ability of BRCA 1 to transactivate a p53-dependent reporter
construct. A more recent study demonstrated that BRG1 and INI1 interact with
p53 via co- immunoprecipitation assays (126). This study also presented data
from transfection experiments that suggested SWI/SNF is necessary for the
activation of p53-mediated transcription.
To determine if Ini1 and p53 cooperate to suppress tumorigenesis , we
crossed mice heterozygous for Ini1 to mice heterozygous for p53 and monitored
the progeny for tumor progression. To our surprise , mice heterozygous for both
tumor suppressors presented with significantly fewer tumors than mice
heterozygous for p53 alone. In addition , the tumor distribution in compound
heterozygous mice was different from that in p53-heterozygous mice. These
data suggest that Ini1 and p53 functionally interact in vivo; however, contrary to
previously published work, it appears that Ini1 may be involved in the repression
of p53-responsive genes.
Materials and Methods
Mouse strains
Ini1- heterozygous mice on a mixed (C57/BI6 X 129) background and p53-
heterozygous mice were described previously (76, 99). Ini1 genotyping was
done on tail DNA as described (77). Genotyping for p53 was done by Southern
blot on EcoRI digested tail DNA (100).
Blastocyst culture
Blastocysts from Ini1 +/-p53-
/- 
intercrosses were flushed at 3.5 days post
fertilization with M15 media (DMEM , 15% fetal calf serum , 100 JlM 
mercaptoethanol , 2 mM glutamine , and 1 X penicillin/streptomycin) and cultured
in tissue culture plates for 96 hr. Outgrowths were genotyped for Ini1 
described previously (76).
Histologic analysis of tumors in mice
Mice were sacrificed when they presented with visible tumors or signs of
wasting. Tumor samples and selected tissues were fixed in 10% buffered
formalin phosphate and processed for paraffn embedding as described
previously (81). Sections were prepared and stained with haematoxylin and
eosin and examined under a microscope.
Western analysis of tumor samples
..., .,. .
Control tissues and tumor samples were homogenized in lysis buffer
containing 50 mM tris-HCI , pH 7. 150 mM NaCI , 0.5% NP-40, 20% glycerol , 1
mM DTT , 1 J1g/mL pepstatin A , 4 J1g/mL leupeptin , and 1 mM PMSF. Extracts
were resolved by SDS-PAGE and western analysis for Ini1 protein was
performed as described previously(48). The p53 western was performed using
Ab-7 from Oncogene.
Results
The generation and characterization of Ini1- heterozygous mice and p53-
heterozgyous mice has been described previously (76, 99). We crossed the
individual heterozygous mice to generate mice heterozygous for both Ini1 and
p53. It has been established that p53-null mice are viable
, while Ini1-null mice
are early embryonic lethal. To determine if loss of p53 rescues embryonic
lethality due to absence of Ini1 , compound heterozygous mice were intercrossed.
No Ini1-null mice were obtained , indicating that absence of p53 is not sufficient to
rescue Ini1-nulllethality (Table 4. 1).
Mice null for the breast cancer susceptibility gene Brca1 are early
embryonic lethal. However, in the absence of p53 , the day of lethality for Brca 1-
null embryos is extended from days 7.5 post-fertilization to days 9.5 post-
fertilzation (78). As mentioned above , functional BRG1 is required for the ability
of BRCA 1 to transactivate a p53-dependent reporter construct, providing a link
Genotype Expected Actual
Ini1 +/+p53+/+
Ini1 +/+p53+/-
Ini1 +/+p53-
Ini1 +/-p53+/+
Ini1 +/-p53+/-
Ini1 +/-p53-
Ini1- p53+/+
Ini1- p53+/-
Ini1- p53-
Table 4. 1: Absence ofp53 does not rescue Ini1-null
embryonic lethality
Ini1+/-p53+/- mice were intercrossed and resultant progeny
genotyped. As shown , no Ini1-null mice were obtained.
between p53 and SWI/SNF pathways (128). To determine if absence of p53 also
allows for an extended survival of Ini1-null embryos Ini1+/-p53-
/- 
mice were
intercrossed and the embryos harvested at day 3.5 post fertilization. These
blastocysts were plated in culture and outgrowths were genotyped 72 hours later.
Ini1+/+p53-
/- 
and Ini1+/-p53-
/- 
blastocysts adhered to the tissue culture
substratum , formed trophectoderm , and expanded their inner cell masses (data
not shown). In contrast Ini1- p53-
/- 
blastocysts did not undergo these
processes , indicating that Ini1-
/- 
embryos are unable to progress beyond the
blastocyst stage in vitro even in the absence of p53.
Because p53-null mice present with tumors particularly fast (100), a
change in the rate of tumor progression is better observed in Ini1-heterozygous
mice on a p53-heterozygous background rather than a p53-null background.
Therefore , we followed Ini1+/- p53+/- mice for tumor development and compared
this rate to those obtained for Ini1- heterozygous mice and p53-heterozygous
mice. To our surprise , the rate of tumorigenesis was reduced in the compound
heterozygous mice compared to p53-heterozygous mice. While all of the
Ini+/+p53+/- mice presented with tumors by 125 weeks of age, only 12 of the 48
Ini1 +/-p53+/- mice presented with tumors (Figure 4. 1). Furthermore , as shown in
Figure 4. , the distribution of tumor spectrums in compound heterozygous mice
was altered relative to p53-heterozygous mice.
Two lymphomas that presented in different Ini1 +/-p53+/- mice were
harvested for Western analysis. As shown in Figure 4.3, both of these tumors
100
p53+/-lni1 +/. (n=48)
p53+/-
Ini1 +/-
Figure 4. 1: Ini1+/-p53+/- mice present with fewer tumors than p53+/-
mice
Mice showing signs of tumorigenesis or wasting were sacrificed and
graphed according to age in weeks. Curves for p53+/- mice and Ini1 +/-
Age (weeks)
mice are consistent with those published (77 100)
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Figure 4. 2: Altered tumor spectrum in Ini1+/-p53+/- mice
The percentage of tumor types was graphed for p53+/- mice and Ini+/-
p53+/- mice. Each color represents the same tumor type in both pie
graphs.
.. 
Ini1
p53
Figure 4.3: Analysis of Ini1 and p53 protein levels in tumors from
Ini1+/.p53+/. mice
Tumor samples and cells were processed for Western analysis as
described in the materials and methods. A204 is an Ini1-deficient cell line
derived from a human malignant rhabdoid tumor. Ini117 is a tumor
sample derived from an Ini1- heterozygous mouse.
lost expression of p53 protein , while only one showed loss of Ini1. Interestingly,
the mouse that presented with the lymphoma devoid of both p53 and Ini1 also
had the onset of a lymph tumor in the mandible region , similar to tumors
described previously in Ini1- heterozygous mice.
Discussion
We crossed Ini1- heterozygous mice to p53-heterozygous mice in an
attempt to dissect a potential mechanism by which Ini1 suppresses
tumorigenesis. We show here the occurrence of a significant latency in the rate
of tumorigenesis in mice heterozygous for both Ini1 and p53 compared to mice
heterozygous for p53 alone. We further show an alteration in the spectrum of
observed tumors. Though we examined only a few tumor samples from the
compound heterozygous mice , both lost expression of p53, while only one lost
expression of Ini1.
Heterozygosity for the tumor suppressor p53 is sufficient to result in tumor
formation in mice without the need for loss of heterozygosity (243).
Tumorigenesis likely is due to the fact that cells heterozygous for p53 have
reduced levels of p53 protein , and hence reduced p53 activity. Our findings
suggest that Ini1 may be involved in the repression of p53 activated genes , such
that cells heterozygous for Ini1 are better able to cope with the reduced levels of
p53. Accordingly, p53 would have to be lost in order for tumorigenesis to occur.
This hypothesis appears to be inconsistent with data published previously, in
which SWI/SNF was shown to be involved in the activation of p53-mediated
transcription (126). However, those studies entailed transfection assays in
transformed cells and the mode of action of SWI/SNF in vivo may be different.
It will be interesting to determine the rate of tumorigenesis in mice
heterozygous for Ini1 and null for p53. These results would indicate whether or
not the presence of p53 is required for the observed suppression of
tumorigenesis. Additioanlly, we are interested in characterizing the biochemical
interactions between Ini1 and p53. Studies are currently underway utilizing Ini1
and p53-targeted mouse embryonic fibroblasts to examine the growth
characteristics and DNA damage response of cells heterozygous for both of
these tumor suppressors.
Chapter V
Compensation of the Ini1 Tumor Suppressor
Introduction
Tumor suppressors play important roles in regulating cellular proliferation
and preventing oncogenesis in higher eukaryotes. Gene targeting experiments
in mice have facilitated the identification and further study of a number of tumor
suppressors. Generally, when mice heterozygous or homozygous-null for a
specific gene present with tumors, the factor encoded by that gene is classified
as a tumor suppressor.
INI1 is a component of the mammalian SWI/SNF chromatin remodeling
enzymes. It was identified simultaneously by two groups as a protein that shares
homology to the yeast Snf5 protein as well as via a yeast two hybrid assay as a
protein that interacts with the HIV integrase protein (107 , 158). The first
evidence implicating INI1 as a tumor suppressor arose when Versteege et al.
identified bi-allelic mutations in IN/1 in malignant rhabdoid tumors, an aggressive
tumor of the soft tissues (245). Mutations in INI1 were found subsequently in
other tumors , such as choroid plexus carcinomas , medullablastomas , central
primitive neuroectodermal tumors , and a few cases of lymphomas (15- , 69,
205). Identification of constitutional mutations in a subset of these tumors further
supported the role of INI1 as a tumor suppressor in humans (17 205).
Gene targeting experiments confirmed that Ini1 also functions as a tumor
suppressor in mice (76 , 115 , 190). While Ini1-null mice are embryonic lethal , 15-
30% of mice heterozygous for Ini1 present with tumors , all of which are poorly
differentiated or undifferentiated tumors with variable rhabdoid features. All
tumors examined show loss of heterozygosity at the Ini110cus. Furthermore
almost 100% of mice bearing a reversibly inactivating conditional allele of Ini1
present rapidly with tumors (189). The vast majority of these tumors have been
classified as CD8+ T-cell lymphomas.
It is interesting to note the difference in tumor penetrance between Ini1-
heterozygous mice and the conditionallni1 mice. These findings indicate that
Ini1 must be lost for tumorigenesis to occur. It has been documented that
heterozygosity for the tumor suppressor p53 is sufficient to result in tumor
formation in mice without the need for loss of heterozygosity (243).
Tumorigenesis likely is due to the fact that cells heterozygous for p53 have
reduced levels of p53 protein. Furthermore , other tumor suppressors , such as
p53, Caveolin- , Fhit, TaR- II (Transforming Growth Factor-a Type II Receptor),
and Sno, also exhibit a marked reduction in protein and/or RNA levels in
heterozygous mice (55 , 62 , 95 , 185, 208). In these cases , haploinsufficiency is
correlated with developmental defects and/or tumorigenesis. In contrast, we
report here that mouse tissues and cells heterozygous for Ini1 had levels of Ini1
protein and RNA equivalent to those in WT tissues and cells. It is possible that
this compensation of Ini1 is responsible for the low tumor penetrance in Ini1-
heterozygous mice.
Because regulation of Ini1 plays an important role in mammalian viability,
we were interested in further characterizing the method by which Ini1 message is
compensated. We show here that the rate of transcription from the Ini1 promoter
is increased in Ini1- heterozygous cells , accounting for the increase in steady-
state message levels. Furthermore, we find that exogenous expression of Ini1
results in a decrease in expression from the endogenous Ini1 promoter
indicating that Ini1 plays a role in the regulation of its own promoter. These
findings extend our current knowledge of the regulation of this tumor suppressor.
Materials and Methods
RT-PCR
Indicated tissues were harvested from one WT mouse and two Ini1-
heterozygous mice and homogenized in Trizol (Life Technologies). RNA was
isolated following manufacturer s protocol. Reverse transcription was performed
using random hexamers and Mu-MLV RT (Invitrogen) with 2 Ilg of RNA for each
tissue. The following oligos were used for amplification: Ini1
gcgtcaagtttcagctggagg and 5'caccagcacctcaggctgtgacgc; GAPDH
gcagtggcaaagtggagattgt and 5'cacggccatcacgccacagctt; 18S rRNA
acttggataactgtggtaattc and 5'aattaccgcggctgctggcacc. Sample amplifications
. ::
were done by real-time PCR to ascertain the linear range for each primer set.
Band intensities were quantitated utilizing ImageQuant software.
Northern analysis
RNA was isolated from WT and Ini1- heterozygous mouse ES cells and
MEFs using Trizol. For each sample, 10 Ilg of mRNA was electrophoresed on a
formaldehyde gel and transferred to GeneScreen plus membrane. Hybridization
was performed at 50 C in 10% Dextran Sulfate, 1.5X SSPE , 1 % SDS, 0.5% Milk
and 625 1l9/mL yeast RNA extract. Blots were washed twice, 20 minutes each
with 10%SDS, 2X SSC at 50 C and once 15 minutes with %SDS, 0.2X SSC at
C. Blots were then exposed to a Phospholmage screen and quantitated
using ImageQuant softare.
Western analysis
Indicated tissues were homogenized in NP-40 Lysis Buffer (50 mM Tris-
HCI , pH 7. 150 mM NaCI , 0.5% NP-40, 20% Glycerol containing 1 mM DTT , 4
1l9/mL leupeptin , 1 1l9/mL pepstatin A, and 1 mM PMSF) and briefly sonicated.
Samples were centrifuged at 4 C for 10 minutes at 10000 X g. Protein extracts
were transferred to fresh Eppendorf tubes and 50 Ilg of each sample was
electrophoreses on SDS-polyacrylamide gels , then transferred to nitrocellulose
membranes. Antibodies against Ini1 , Brg1 , Brm , and Tubulin have been
described previously (48 , 76). Blots were developed using Amersham ECL
reagent, exposed to autoradiograph film , which were then scanned and
quantitated using ImageQuant software.
Half-Life Assays
WT and Ini1- heterozygous MEFs were grown to 80% confluency prior to
addition of 10 ug/mL Actinomycin D (Sigma). Cells were harvested at 2 hour
intervals between 0-12 hours after addition of Actinomycin 0 and again for a final
time-point at 24 hours. Samples were processed for RNA using Trizol reagent
(Life Technologies) following manufacturer s protocol. Reverse transcription was
performed using random hexamers and Mu-ML V RT (lnvitrogen) with 2 ug of
RNA for each time-point. Ini1 , GAPDH , and 18S rRNA were amplified utilizing
real-time PCR (MJ Research) with Qiagen SYBR-green reagents. Primers used
are described above. The quantity of starting material for each product at each
time-point was determined using software provided with real-time PCR machine.
Ini1 and GAPDH are graphed relative to 18S rRNA Results shown are the
average of two experiments done in triplicate for each time-point. Time 0 was
arbitrarily set to 1 , and the remaining time-points were adjusted accordingly.
Nuclear runon transcription assay
Nuclear runon transcription assays were done as described previously by
Schubeler and Bode (ww.biomednet.com). Wild-type and Ini1-heterozygous
mouse embryonic fibroblasts (-4 X 10 ) were collected by trypsination into 10 mL
conicals and centrifuged at room temperature at 200 X g for 5 minutes. Cell
pellets were washed once with phosphate-buffered saline and collected by
centrifugation at 200 X g for 5 minutes at 4 C. 5 mL of cold lysis buffer (10 mM
Tris- HCI , pH 7.4 , 10 mM NaCI , 3 mM MgC!2, 0.5% NP40) were added to the cell
pellets , which then were vortexed at low speed and incubated on ice for 3
minutes. Nuclei were collected by centrifugation at 500 X g for 5 minutes at 4
These lysis steps were repeated three more times. The final nuclear pellets were
resuspended in 100 J.L nuclear freezing buffer (50 mM Tris-HCI , pH 8.3, 40%
glycerol S mM MgCI , 0. 1 mM EDTA) and either used directly or frozen in liquid
and stored at
Nuclei suspensions were mixed with 30 J.L of 5X runon buffer (25 mM
Tris-HCI , pH8, 12.5 mM MgCI , 750 mM KCI , 1.25 mM each of ATP , GTP , and
CTP , and 100 J.Ci a- UTP) and incubated at 30 C for 30 minutes. DNA was
digested by the addition of 15 units of RNase-free DNasel and incubation at 30
for 15 minutes. RNA was isolated using Trizol reagent. Reaction mixtures (- 150
J.L) were transferred to 2 mL Eppendorf tubes containing 1.5 mL of Trizol and
shaken for 2 minutes. Then , 300 J.L CHCIa were added and the mixtures were
shaken for another 5 minutes. Samples were centrifuged at 12000 X g for 15
minutes at 4 C. The aqueous phase was transferred to a fresh Eppendorf tube
containing 800 J.L of isopropanol , mixed for 5 minutes at room temperature , and
RNA pelleted by centrifugation at 12000 X g for 15 minutes at 4 C. RNA pellets
were washed twice with 75% ethanol , air dried , and dissolved in 100 ilL water.
Incorporation of p was determined by Cerenkov counting on a 1 ilL aliquot.
For hybridization , plasmid fragments of interest were dot blotted manually
to GeneScreen plus membrane. NaOH and EDT A were added to linearized
cDNAs corresponding to exons 1-3 of Ini1 , full- length GAPDH , and empty vector
control to a final concentration of 0.4 M and 10 mM , respectively. Samples were
boiled for 10 minutes , chilled on ice and then added in 2 ilL aliquots to
membrane that had been cut to size and wetted in dH20. The membrane then
was rinsed in 2X sse and DNA cross- linked using a Stratalinker.
Prehybridization was done for at least 2 hours at 60 C in 1 % SDS, 10% dextran
sulfate , 1.4 M NaCI , 325 1l9/mL each of salmon sperm DNA and yeast RNA
extract. Equivalent amounts of runon RNA (-3 X 10 counts/min) from WTand
Ini1-heterozygous cell extracts were added to blot and hybridization was
performed for 16-42 hours. Blots then were washed: 2X SSC (2 X 5 min , RT);
2X SSC, 1 % SDS (15 min , 65 C); 2X sse (5 min , RT); 2X sse, 10 1l9/mL
RNase A (10 min , 37 C); 2X SSC (5 min , RT); 0. 1 X SSC (3 X 5 min , RT) and
exposed to Phospholmage screen. Hybridization was quantitated using
ImageQuant software.
Beta-galactosidase assay
BOSC cells were transfected with retroviral pBABE vector or retroviral
pBABE vector encoding a FLAG-epitope-tagged Ini1 using Fugene reagent
according to manufacturer s protocol. After 48 hours, the transfected BOSC cell
supernatants were used to infect Ini1-heterozygous mouse embryonic fibroblasts
at 80%. 48 hours post- infection , blasticidin (10 ug/mL) was added to the MEFs
to select for infected cells. After 48 hours of selection , adherent cells were
washed with 1 X PBS twice. Residual PBS was removed and sufficient volume of
1 X Reporter Lysis Buffer (Promega) to cover the cells. Cells were incubated at
room temperature for 15 minutes and then transferred to an Eppendorf tube.
Tubes were centrifuged at top speed for 2 minutes at 4 C and supernatants
transferred to fresh tubes. An equal volume of 2X assay buffer (200 mM sodium
phosphate buffer, pH 7. 3, 2 mM MgCb, 100 mM -mercaptoethanol , and 1.
mg/mL ONPG) was added to each cell lysate and incubated at room temperature
until the first sample turned a faint yellow. Reactions were stopped with 0.
Sodium Carbonate and absorbances read at 420 nm.
Results
We previously generated mice heterozygous for Ini1 utilizing an
inactivating retroviral insertion vector (76). During the course of this study, we
observed that various tissues from Ini1- heterozygous mice had levels of Ini1
protein equivalent to those from wild-type (WT) tissues (Figure 5. 1 a). 
determine if compensation of Ini1 was occurring at the level of protein regulation
or mRNA regulation , we looked at steady state levels of Ini1 mRNA in various
tissues from WT and Ini1- heterozygous mice by RT-PCR. The number 
amplification cycles used was determined to be in the linear range by real-time
PCR (data not shown). As shown in Figure 5. 1 b , WT and Ini1-heterozygous
tissues contain roughly equivalent levels of Ini1 message , indicating that
modulation of Ini1 mRNA accounts for the observed compensation. We next
looked at the levels of Ini1 protein and message in WT and Ini1-heterozygous
mouse embryonic stem (ES) cells and mouse embryonic fibroblasts (MEFs).
Similar to results obtained for mouse tissues , cells heterozygous for Ini1 had
roughly equivalent levels of Ini1 protein and RNA as WT cells (Figure 5.2).
We hypothesized that compensation of Ini1 mRNA was achieved by either
an increase in the stability of Ini1 mRNA or an increase in the rate of transcription
from the Ini1 promoter. We first compared the half- life of Ini1 mRNA in WT cells
to that of Ini1 mRNA in Ini1- heterozygous cells. Cells were exposed to 10 ug/ml
Actinomycin D and then harvested at various intervals until 24 hours. Ini1 and
GAPDH mRNA decay was monitored by real-time PCR. As shown in Figure 5.
the decay rate of Ini1 message in Ini1- heterozygous cells is the same as that in
WT cells , suggesting that Ini1 compensation is not mediated by an increase in
Ini1 mRNA stability. This is not surprising since Ini1 message appears to be
long- lived in MEFs.
We next looked at the rate of transcription of Ini1 in WT and Ini1-
heterozygous cells by a run-on transcription assay. Newly synthesized RNA
from WT and Ini1- heterozygous cells was labeled in vitro with UTP and used
to probe cDNAs immobilized on a membrane. As described in our previous
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Figure 5.1: Tissues from Ini1-heterozygous mice have similar levels of
protein and mRNA as wild-type mice
Indicated tissues from wild-type mice and Ini1-heterozygous mice were
harvested and processed for Western analysis (A) or RT-PCR (B.) as
described in the materials and methods. The intensity of each protein or
cDNA band was determined using ImageQuant softare.
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Figure 5.2: Ini1-heterozygous cells have similar levels of Ini1 protein and
RNA as wild-type cells
Wild-type and Ini1- heterozygous ES cells or MEFs were processed for Western
analysis (A.) or Northern analysis (B.) as described in the materials and
methods. Intensity of each protein or RNA band was determined using
ImageQuant software.
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Figure 5.3: The decay rate of Ini1 message is not altered in Ini1-heterozygous
cells
Wild-type and Inn- heterozygous cells were exposed to Actinomycin D and harvested at
12 16 20 
Time (hours)
various time-points thereafter. Message levels of Ini1 and GAPDH were determined by
real-time PCR and graphed relative to 18 rRNA
manuscript, Ini1-heterozygous cells contain one wild-type allele of Ini1 as well as
an allele of Ini1 that is disrupted by the insertion of a retroviral vector within intron
3. This insertion results in the synthesis of two fusion transcripts: one containing
exons 1-3 of Ini1 fused to 13-galactosidase and another containing puromycin
fused to the remaining exons of Ini1. In order to identify only those transcripts
generated from the Ini1 promoter, a cDNA of Ini1 corresponding to exons 1-
was used in the run-on assay. GAPDH cDNA and empty plasmid vector were
used as controls. After hybridization and extensive washing, blots were exposed
to a Phospho Image screen , scanned, and quantitated utilzing ImageQuant
software. As illustrated in Figure 5.4 Ini1- heterozgous cells contain almost
double the amount of radiolabeled Ini1 RNA as WT cells. Thus , the rate of
transcription from the Ini1 promoter is increased in Ini1- heterozygous cells
accounting for the observed compensation.
To determine if Ini1 plays a role in the regulation of its own transcription
we exogenously expressed Ini1 in the Ini1- targeted MEFs and examined the
effect on Ini1- promoter activity. We utilized the fact that these cells contain a 13-
galactosidase gene cassette under the control of the Ini1 promoter. The activity
of the Ini1 promoter was monitored in Ini1- heterozygous cells infected with either
a retrovirus encoding Ini1 or the empty retroviral vector control by assaying for 13-
galactosidase activity using a spectrophotometric assay described in the
Materials and Methods. We found that cells infected with Ini1 exhibited reduced
13-galactosidase activity as compared to cells infected with empty retroviral vector
Ini1 +/-
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Figure 5.4: The rate of trnscription of Ini1 is increased in In;1-heterozgyous cells
A. Nuclear run-on assays were performed as describe in the materials and methods.
Representative blots demonstrating increased levels of newly synthesized Ini1 RNA in 
Ini1-
heterozygous cells.
B. Graphical representation of two nuclear run-on experiments. The intensity of Ini1
relative to GAPDH was arbitrarily set to 1 for WT samples and the intensity of Ini1/GAPDH
for Ini1-heterozygous samples was set accrdingly.
Exp. A Exp. B
a 0.
Empty 1nil Empty 1nil
vector vector
Ini1
FLAG
Tubulin
Figure 5.5: The expression level of Ini1 is tightly regulated
A. Ini1-heterozygous cells were infected with a retroviral vector encoding Ini1 or an empty
retroviral vector. Relative gal activity was determined as described in the materials and
methods. The graph represents results from two experiments done in triplicate.
B. Expression of FLAG epitope-tagged Ini1 in cells infected with Ini1-encoding retroviral
vector.
(Figure 5.5). Because we measurined activity of the galactosidase protein
which is very stable, it is likely that transcription from the Ini1 promoter is reduced
even further than the reduction observed for galactosidase activity. Thus , it is
clear that Ini1 plays a role , direct or indirect, in the regulation of its own
transcription.
Discussion
Here we report that the mammalian tumor suppressor Ini1 is upregulated
in Ini1- heterozygous cells by an increase in the rate of transcription from the Ini1
promoter. Furthermore , Ini1 appears to playa role in the regulation of its o
promoter as exogenous expression of Ini1 results in decreased activity from the
Ini1 promoter. The observed transcriptional compensation for 
Ini1 heterozygosity
likely contributes to the low tumor penetrance in Ini1- heterozygous mice , as the
increase in transcription rate from the single functional allele prevents potentially
deleterious effects due to a decreased level of Ini1.
In Drosophila dosage compensation is achieved by increasing the rate of
transcription of genes on the single X chromosome in males to approximately
double that of genes on each of the two X chromosomes in females. In
mammals, few cases involving a compensating increase in transcriptional rate
have been documented. It has been postulated that dosage compensation of the
X chromosome in Drosophila males originally evolved on a gene to gene basis
(150). As such , it is reasonable that gene dosage compensation in mammals
also exists on a gene to gene basis. It is likely that such events have not been
characterized previously in mammals since phenotypic differences should not be
observed in heterozygous individuals when the targeted gene is upregulated. In
the case of Ini1 , the non-targeted allele must be disrupted before any phenotypic
difference is observed.
Clearly, it would be interesting to determine the exact mechanism by
which the rate of transcription of Ini1 is increased in Ini1- heterozygous cells. To
date, the promoter of Ini1 has not been defined. A database search for known
consensus binding sites of transcription factors within the region upstream of the
Ini1 start site yielded no obvious candidates that may be responsible for the
observed upregulation. It should be noted that while dosage compensation in
Drosophila has been studied extensively, the exact mechanism by which this
compensation occurs has yet to be elucidated.
Chapter VI
Summary
It has become apparent that INI1 plays a critical role in mammalian
development and tumor suppression. Work presented in this thesis has shown
that Ini1 is essential for murine embryogenesis. Mice homozygous-null for Ini1
fail to adhere to substratum , form trophectoderm , and expand their inner cell
mass. Because embryonic lethality occurs so early, it is difficult to determine the
function of Ini1 at this stage of development. Data from another group show that
Ini1 is maternally deposited in oocY)es (115). These maternal stores of Ini1 can
be detected up to day 3.5 post fertilization , near the time at which null embryos
die. It is possible that Ini1 is required for general cell viability rather than for a
specific function at a determined developmental time-point. This is supported
further by the fact that conditionallni1-knockout mice die shortly after inactivation
of Ini1 expression (189).
We also have shown that mice heterozygous for Ini1 are predisposed to
poorly differentiated or undifferentiated sarcomas with variable rhabdoid features.
All of the tumors examined show loss of heterozygosity at the Ini110cus.
Although the Ini- heterozygous mice do not recapitulate completely the human
tumors associated with mutations in Ini1 they have provided a useful model
system for addressing the function of Ini1 in suppressing tumorigenesis.
Ini1 may function as a tumor suppressor by interacting with other known
tumor suppressors. We focused on Rb and p53 because there were existing
data in the literature linking these tumor suppressors to SWI/SNF and/or INI1.
Most of these data , however, were generated using transformed cell lines. We
were able to address the in vivo functions of Ini1 by utilizing the Ini1-
heterozgyous mice in crosses with mice heterozygous for either Rb or p53.
Data we obtained suggest that Ini1 and Rb do not cooperate to suppress
tumorigenesis. This is consistent with transfection experiments in which INI1 is
not required for the ability of Rb to growth arrest cells derived from human
malignant rhabdoid tumors (244). However, it appears that Ini1 may contribute to
the progression of Rb-deficient pituitary tumors , as mice heterozygous for both
Rb and Ini1 present with tumors that have a morphology altered from that of
typical pituitary adenomas.
When we generated mice heterozygous for both Ini1 and p53, we were
hoping to discover that these two factors share overlapping pathways in
suppressing tumorigenesis. On the contrary, we found that Ini1 may be involved
in the repression of p53-responsive genes, such that p53 activity is upregulated
in Ini1-heterozygous cells. This was a surprising discovery in lieu of the fact that
previous data suggested that SWI/SNF is required for p53-mediated
transcriptional activation (20, 126). However, it is important to keep in mind that
these previous studies were done using transfection assays in transformed cells.
'('
It will be interesting to further explore the function of Ini1 on p53 activity in mouse
embryonic fibroblasts with targeted deletions in Ini1 and/or p53.
The promoter of INI1 has yet to be identified and as such , little is known
about the regulation of this gene. As presented in this thesis, we were able to
show that the expression of Ini1 is regulated to ensure that relatively constant
levels of Ini1 are present at a given time. Therefore , when one allele of Ini1 
disrupted, the functional allele is transcriptionally upregulated. Likewise , when
Ini1 is expressed exogenously, the endogenous alleles are down-regulated. The
fact that Ini1 is compensated in heterozygous cells and tissues has implications
on other aspects of this thesis. For instance, this compensation may explain why
only 20% of mice heterozygous for Ini1 present with tumors , as loss of
heterozygosity may be required for tumor development. Furthermore, care wil
have to be given to interpretations of the crosses described above. If the steady-
state levels of Ini1 protein are equivalent in wild-type and Ini1-heterozygous cells
why is there a difference in the rate of tumorigenesis between Ini1 +/+p53+/- mice
and Ini1+/-p53+/- mice? One possibility is that the compensation is not exact. In
fact, we found that Ini1 mRNA levels in Ini1- heterozygous cells were
approximately 85% of those in wild-type cells. Another possibility is that the
compensation of Ini1 is disrupted in p53-heterozygous tissues. Preliminary
Western analysis suggests that this is not the case. Lastly, it is possible that the
mechanism by which Ini1 is upregulated also affects p53 or other factors that
may playa role in stimulating p53 activity.
100
Of course , there is much yet to learn about the normal activities of INI1.
Continued research hopefully will dissect the pathways in which INI1 plays a role,
both in cell viability and tumor suppression. It also will be important to determine
if INI1 functions solely in the context of the SWI/SNF complexes , or if it has a
distinct role.
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Appendix A
Preliminary Data
The Role of Brg1 in Early Mammalian Development
In yeast, the activity of the SWI/SNF enzyme is required for the expression
of the mating type switch gene HO and the SUC2 invertase required for sucrose
fermentation (23, 167 216). Not surprisingly, there are no mammalian homo logs
of these genes. As such , one of the major thrusts of our lab has been to identify
the mammalian gene targets of SWI/SNF.
We have been interested particularly in the gene regulation events
occurring during mammalian embryogenesis that may require SWI/SNF activity.
Mice homozygous-null for the ATPase subunit Brg1 of the mammalian
SWI/SNF complex are early embryonic lethal , with death occurring between days
5 and 6.5 post-fertilization (27). Because lethality occurs so early, it is not
possible to generate mouse embryonic fibroblasts lacking Brg1. Likewise Brg1-
null embryonic stem (ES) cells are not viable , precluding the ability to study the 
vitro differentiation of cells lacking Brg1 protein. To circumvent this obstacle , we
generated mouse ES cells that constitutively expressed a dominant negative
version of human BRG1 and examined the ability of these cells to differentiate 
vitro.
Mouse embryonic stem cells are pluripotent cells that can differentiate into
a variety of lineages. When plated in methylcellulose , ES cells wil differentiate
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into the three germ layers (endoderm , mesoderm , and ectoderm), muscle
lineages , hematopoietic lineages , and neuronal lineages. The gene regulation
events that occur throughout the differentiation process can be monitored by RT-
PCR for various lineage-specific factors. We found that mouse ES cells
expressing dominant negative BRG1 were defective in their ability to
differentiate. However, preliminary experiments indicate that the expression of
only a subset of germ layer markers was altered, suggesting that the inability of
these cells to differentiate properly was not due to a global defect in transcription.
Rather, it appears that SWI/SNFactivity regulates the expression of specific
factors required for mammalian development.
Materials and Methods
Generation of Cell Lines
AB2.2 mouse embryonic stem cells were electroporated with a linearized plasmid
bearing a FLAG epitope-tagged , dominant-negative version of BRG1 (K798R)
under control of a retroviral L TR. Puromycin-resistant clones were harvested for
Western analysis for FLAG as described previously (49). Of 85 puromycin-
resistant colonies screened , only one expressed significant levels of dominant-
negative BRG1 protein. 3E3 is a FLAG-expressing clone , while E1 is a clone
that was puromycin resistant but did not express detectable levels of FLAG-
tagged protein.
Differentiation of ES Cells
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ES cells of interest were grown to no more than 60% confluency on mitotically
inactivated fibroblasts engineered to express leukemia inhibitory factor (LlF). 
day 0 of differentiation ES cells were trypsinized and resuspended in DMEM with
15% FCS and 150 J.M monothiolglycerol (MTG). Cells were plated in 1 %
methylcellulose media in DMEM + 15% FCS + 150 J.M MTG at 20 000 cells/ 60
mm Petri dish.
RT-PCR
At indicated times , cells were harvested and processed for RNA using Trizol (Life
Technologies), following the manufacturer s protocol. For each time-point , 1 mg
of RNA was subjected to reverse transcription using AMV-RT (Gibco) and oligo
dT. Germ layer and control markers were amplified using the following primers:
Hprt , F , 5' GCTGGTGAAAAG GACCTCTCGAAGTG- , R , 5' ATGGCCACAGG
ACTAGAACACCTGC- , internal (I), 5' CAAAGCCTAAGATGAGCGCAAGTT
, Ta 55 oC; Sox2 , F , 5' GTTACCTCTTCCTCCCACTCCAG- , R , 5' CCCG
CCCTCCCCGCCGCCCTCA G- , I, 5' GAGGGCTGGACTGCGAACTGGAGA
, Ta 58 oC; Brachyury, F , 5' TGCTGCCTGTGAGTCATAAC- , R , 5' ACCA
GGTGCTATATATTGCC- , I , 5' GCTGGGAGCTCAGTTCTTCGAGGC- , Ta
54 oC; Hnf1 , F , 5' TTCTAAGC TGAGCCAGCTGCAGACG- , R , 5' GCTGAGGT
TCTCCGGCTCTTCAGA- , I , 5' TGACACGGA TGACGA TGGGGAAGAC-
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Ta 62 oC; Hnf4 , F , 5' ACACGT CCCCATCTGAAG- , R , 5' CTTCCTTCTTCAT
GCCAG- , I , 5' TCGAGCTGTG ACGGCTGCAAGGGGT- , Ta 55 oC. PCR
products were resolved on 2% agarose gels , transferred to nylon membrane
(GeneScreen), and probed with the indicated , radiolabeled internal primers.
Eryhrocyte markers were amplified using the following primers: major globin
, 5' CACAACCCCAGAAACAGACA- , R , 5' CTGACAGATGCTCTCTTGGG-
i2 globin
, F , 5' GGAGAGTCCATTAAGAACCTAGACAA- , R , 5' CTGTCAATTC
ATTGCCGAAGTAC- H1 globin , F , 5' CTCAAGGAGACCTTGCTCA-
, 5' AGTCCCCA TGGAGCT AAAGA- . Products were resolved on 2% agarose
gels and stained with ethidium bromide.
Results
In order to disrupt SWI/SNF activity, a mouse embryonic stem cell line
was generated that constitutively expressed an ATPase-defective form of human
BRG1 (DN-BRG1) under control of a retroviral L TR (Figure A.1). The ATPase-
inactive form of BRG1 previously was shown to interact with other components of
the SWI/SNF complex in 3T3 cell lines (50), suggesting that the mutant protein
depletes functional SWI/SNF complexes.
The DN-BRG1 expressing 3E3 cells were plated in methylcellulose
medium to induce differentiation. As controls , wild-type AB2.2 ES cells as well
as a cell line (1 E1), derived from a clone that had been electroporated but did not
express detectable levels of DN-BRG1 protein , were differentiated. When
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Figure A.1. 3E3 ES cells constitutively express dominant negative BRG1.
A. Comparison of conserved ATPase domain of mammalian BRG1 and yeast SWI2.
lysine boxed is mutated to arginine in the dominant negative BRG1. B. Western
analysis showing expression of FLAG-tagged DN-BRG1 in 3E3 but not 1E1 cell lines.
105(-) is a 3T3 cell line that inducible expressed DN-BRG1.
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differentiated in vitro, ES cells form clusters called embryoid bodies. As shown in
Figure A.2 , WT ES cells and 1 E1 cells formed embryoid bodies that developed
normally with time. However, while 3E3 embryoid bodies were indistinguishable
from those of WT and 1 E1 cells at day 3 post-differentiation , they failed to
develop significantly beyond day 3. The defect was more severe than just a
delay in the differentiation process as the 3E3 cells remained morphologically the
same from day 7 to day 14 post-differentiation.
Embryoid bodies were harvested at days 3, 5, 10, and 12 , and processed
for RNA. The endodermal markers Hnf1 and Hnf4, the mesodermal marker
Brachyury, and the ectodermal marker Sox2 were amplified and subjected to
Southern blot analysis for visualization. Hprt was amplified as a loading control.
As shown in Figure A.3, the expression patterns of Hnf1 and Sox2 in ES cells
expressing DN-BRG1 were similar to those in wild-type ES cells. However, the
expression patterns of Hnf4 and Brachyury were altered in the DN-BRG1 ES
cells. The expression of Brachyury was delayed in the 3E3 cells , suggesting that
SWI/SNF is required for proper kinetics of Brachyury expression. In contrast
Hnf4 was expressed earlier in the 3E3 cells , suggesting that SWI/SNF normally
plays a role in the repression of this gene.
We also examined the ability of the 3E3 cells to differentiate into eryhroid
lineages. In murine cells there are four globin genes: two fetal globins , Ey2 and
j3H1 , and two adult globins , j3-major and j3-minor, all of which are under control of
a common locus control region (Figure A.4). After 12 days of differentiation in
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Figure A.2. ES cells expressing dominant negative BRG1 are severely impaired in
their ability to differentiate.
Wild-type AB2.2 ES cells , 1 E1 (negative control) ES cells , and 3E3 (DN-BRG1) ES
cells were differentiated in methylcellulose medium , harvested at indicated time-
points and photographed under phase microscopy.
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Figure A.3. The express of a subset of germ layer markers is altered in the presence of
dominant negative BRG1.
Wild-type and 3E3 ES cells were differentiated in methylcellulose , harvested at
indicated time-points , and processed for RNA. RT-PCR and Southern blot hybridization
were performed for listed markers using primers described in the Materials and
Methods.
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Figure A.4. Murine j3-globin locus.
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Murine f3-globin Locus
Ey2 I3H1 l3- jorH l3- ino+-
Cartoon illustrating murine b-globin locus. LCR: locus control region. HS1-
DNase I hypersensitive sites.
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methylcellulose , embryoid bodies express all four globins. Therefore , we
harvested wild-type and 3E3 embryoid bodies at day 12 of differentiation and
examined the expression levels of E , and -major globins. As shown in
Figure A.5 , the levels of the fetal globins were decreased in the 3E3 cells , while
the adult -major globin was unaltered.
Discussion
Mice homozygous null for Brg1 are embryonic lethal between days 3.
and 6.5 post-fertilization (27). Due to the complexity of harvesting embryos at
these stages in development , it is diffcult to elucidate the pathways in which
SWI/SNF functions in vivo. However, it is possible to utilize in vitro differentiation
of mouse embryonic stem cells to examine more easily the requirement for
SWI/SNF activity in specific gene regulation events. Although Brg1-null ES cells
are not viable , we were able to disrupt SWI/SNF activity by constitutively
expressing a dominant negative version of BRG1. It is interesting to note that
only one of the 85 clones screened expressed DN-BRG1 protein at significant
levels , suggesting that there is a requirement for a basal level of SWI/SNF
activity to ensure cellular viability. In fact, further attempts to generate an ES cell
line that expresses the dominant negative BRG1 have been unsuccessful.
Upon differentiation of the ES cells , we found that there were striking
morphological differences between the embryoid bodies derived from wild-type or
control ES cells and those derived from ES cells expressing DN-BRG1. The
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Figure A.5. The expression of fetall'-globins is inhibited in the presence of
dominant negative BRG1.
Wild-type and 3E3 ES cells were plated in methylcellulose. At day 12 of
differentiation, embryoid bodies were harvested for RNA. RT-PCR was done
using primers described in the Materials and Methods.
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development of embryoid bodies that expressed DN-BRG1 was severely
retarded. We examined the expression pattern of a selection of germ layer
markers in an attempt to equate a defect in SWI/SNF activity to the observed
morphological differences. Interestingly, the expression of a subset , but not all
of the germ layer markers was altered. Specifically, the endoderm marker Hnf4
was expressed at much earlier time-points in the embryoid bodies derived from
DN-BRG1 ES cells compared to those derived from wild-type counterparts. This
finding suggests that SWI/SNF normally functions to inhibit Hnf4 at early time-
points in mammalian development. The possibility that SWI/SNF inhibits Hnf4
expression is not surprising since data obtained from DNA microarray expression
analysis indicate that SWI/SNF appears to be involved in the repression of just
as many genes as it activates (224). Furthermore , mammalian SWI/SNF
components also have been shown to playa role in the repression of c-fos and
some E2F-regulated genes (165, 235, 253).
The expression pattern of the mesoderm marker Brachyury also was
altered. In particular, the expression kinetics of Brachyury appeared to be
delayed in the DN-BRG1 embryoid bodies. The subtle changes in Brachyury
expression may be due to the fact that SWI/SNF activity is inhibited partially and
not completed abrogated. However, it is interesting to consider the possibility
that SWI/SNF may regulate subtle changes in gene expression that have the
potential to lead to drastic phenotypic abnormalities in development when
misregulated.
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We also examined the effect of DN-BRG1 on the expression of the beta-
globin genes E , and -major. It is interesting to note that expression of the
fetal glob ins E1' and f3H1 was inhibited while expression of the adult -major
globin was unaffected in the presence of DN-BRG1. This is particularly intriguing
since all of the beta-globin genes are under the regulation of the same locus
control region. It is unclear how SWI/SNF differentially modulates the expression
of the various globin genes. As depicted in Figure there are several DNase I
hypersensitive (HS) sites located in the beta-globin LCR (73). The HS site that is
more prevalent at a given point in development depends on which beta-globin is
expressed more highly, suggesting that the chromatin structure within the beta-
globin LCR may be differentially remodeled. One of the future aims of this study
will be to examine the effect of DN-BRG1 on the sensitivity of these various sites
to DNase I.
There are several experiments we would like to conduct to complete this
study. First, we would like to generate another clone that expresses dominant
negative BRG1 to corroborate the results presented here. Alternatively, ES cell
lines could be generated that express an inducible DN-BRG1. It also would be of
interest to examine the expression of more germ layer markers to determine if
there is a link between the genes regulated by SWI/SNF. The potential also
exists to enrich the embryoid bodies for eryhrocytes using eryhropoietin in the
differentiation medium , muscle cells using DMSO, and/or neuronal cells using
retinoic acid. By examining the effect of disrupting SWI/SNF activity on the
differentiation of a variety of cell lineages, we will gain a more complete
understanding of the processes in which SWI/SNFfunctions.
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Appendix B
Preliminary Results
Hydroxyl Radical Footprinting of SWI/SNF-Remodeled Mononucleosomes
The mechanism by which SWI/SNF alters chromatin structure is unclear.
Early data led some to suggest that SWI/SNF either removes or rearranges the
H2A-H2B dimers to facilitate remodeling (180). More recent studies demonstrate
that SWI/SNF is able to induce nucleosome sliding or octamer transfer (104
183). It has been postulated that SWI/SNF induces nucleosome sliding by first
inducing a twist in the DNA that is then diffused throughout the nucleosomal
DNA. However, experiments utilizing nucleosomes that contain branched DNA
as a steric block to twisting and a nick that allows the dissipation of torsional
stress within the nucleosome indicate that a twist-diffusion mechanism is not
required for remodeling by SWI/SNF (6). Furthermore , cross- linking reagents
demonstrate that the octamer need not be perturbed in order for SWI/SNF to
alter the DNase I cleavage pattern or restriction enzyme accessibility of in vitro
assembled mononucleosomes or arrays (22).
Digestion of in vitro assembled , rotation ally phased mononucleosomes
with DNase I yields a 10 base pair ladder when resolved on a denaturing
polyacrylamide gel. This cleavage pattern is altered when the
monbnucleosomes are pre- incubated with SWI/SNF in the presence of ATP
suggesting a fairly drastic effect of SWI/SNF activity (43, 98 , 126). However
140
DNase I is a large enzyme that needs to bind DNA to cleave and as such may
contribute to the alteration of the mononucleosomes in response to SWISNF
activity. In contrast, hydroxyl radicals are small chemical moieties that do not
bind DNA. Therefore hydroxyl radical cleavage may provide a more accurate
depiction of the of SWI/SNF activity on mononucleosomes.
We monitored SWI/SNF activity by utilizing hydroxyl radical digestion of
mononucleosomal templates. Unlike the DNase I digestion pattern , the hydroxyl
radical digestion pattern of rotationally-phased mononucleosomes was unaltered
in the presence of SWI/SNF and ATP. This finding suggests that the mechanism
of remodeling by the SWI/SNF enzymes may be more subtle than currently
believed.
Materials and Methods
Mononucleosome assembly
Mononucleosomes were assembled by salt dilution , as described
previously (98), using a 154 base pair EcoRI/Rsal fragment corresponding to the
Xenopus borealis somatic 5S RNA gene. The assembly reaction included 0.45
g of labeled DNA fragment (end- labeled by Klenow fill- in with (
p)-
dATP at
the EcoRI end), 5 g of Haeill-digested pUC18 DNA, and 8. g of core histone
octamers purified from HeLa cell nuclei. Assembled mononucleosomes were
purified from unincorporated DNA over a 5 mL, 5-30% glycerol gradient
containing 50 mM Tris , pH 7. , 1 mM EDT A, and 0. 1 mg/mL BSA.
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Cleavage reactions
For both DNase I and hydroxyl radical cleavage , 0.3 ng (1.2X1 0-1 0 M) 
labeled nucleosomes were added to reactions of 25 flL total volume containing
12 mM HEPES, pH 9, 60 mM KCL, 7 mM MgCI , 15% glycerol , 0.5 fl9 BSA , 10
mM Tris-HCI , pH 7. 5, 0.6 mM DTT , and 0.06 mM EDTA. Where indicated
reactions also contained 100-400 ng of SWI/SNF purified from HeLa cell nuclei
i '
as described previously (98) and 0.02 mM ATP. Reactions were incubated at
C for 30 minutes. For DNase I cleavage , RQ1 DNase I was added to naked
DNA at 0.01 units and to nucleosomes at 0. 1 units for 2 minutes at room
temperature. Reactions were stopped with 2 flL of 0.5 M EDTA. For hydroxyl
radical digestion , 3.5 flL each of 10 mM (1 mM for naked DNA) Fe-EDTA, 200
mM (20 mM for naked DNA) sodium ascorbate , and 30% (3% for naked DNA)
were added to the sides of the tubes , tapped in , and incubated for 3
minutes at room temperature. Reactions were stopped with 3.5 flL of 50%
glycerol , 10 mM EDT A. Samples were prepared for electrophoresis as described
previously (98) and resolved on an 8% polyacrylamide/urea gel.
Results and Discussion
A 154 base pair 5S rRNA fragment from Xenopus borealis was assembled
into mononucleosomes , incubated in the presence of SWI/SNF +/- ATP , and
digested with DNase I or hydroxyl radicals. While the DNase I cleavage pattern
was altered in the presence of SWI/SNF + ATP , the hydroxyl radical cleavage
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pattern remained unaltered (Figure B. 1). DNase I cleavage was done in the
presence of the hydroxyl radical components to verify that SWI/SNF was not
inactivated (data not shown).
The hydroxyl radical cleavage data suggest that SWI/SNF is not
drastically altering the mononucleosome structure. The nucleosomal DNA
appears to maintain its rotational phasing; however, at this time we cannot rule
out the possibility that the octamer has shifted 10 base pairs , or increments
thereof, along the length of the DNA. Another possibility is that the SWI/SNF
enzyme weakens the histone-DNA contacts. The observed alteration of the
DNase I footprint may be a consequence of the DNase I enzyme itself binding to
the " remodeled" nucleosome further perturbing the nucleosome structure.
Hydroxyl radical digestion of mononucleosomes +/- SWI/SNF in the presence of
a DNase I mutant (H252Q) that is able to bind DNA but is cleavage defective will
be done to determine if binding of DNase I alters the digestion pattern.
Weakening of histone-DNA contacts also would allow the binding of transcription
factors or restriction endonucleases to the altered DNA. However, the
mechanism by which SWI/SNF may weaken the histone-DNA contacts has yet to
be determined.
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Figure B.1. SWI/SNF does not alter hydroxyl radical cleavage pattern of
rotationally phased mononucleosomes.
A 154 base pair fragment from the Xenopus borealis 5S rRNA gene was end-
labeled with p and assembled into mononucleosomes in vitro.
Mononucleosomes were digested with DNase I or hydroxyl radicals after
incubation with SWI/SNF +/- ATP. Purified DNA was resolved on an 8%
denaturing gel.
